Chemical Investigations of Diabetes Mellitus, Malaria, and Castrate-Resistant Prostate Cancer by Lookadoo, Maggie Sparks
University of Tennessee, Knoxville 
TRACE: Tennessee Research and Creative 
Exchange 
Masters Theses Graduate School 
12-2015 
Chemical Investigations of Diabetes Mellitus, Malaria, and 
Castrate-Resistant Prostate Cancer 
Maggie Sparks Lookadoo 
University of Tennessee - Knoxville, mlookado@vols.utk.edu 
Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes 
 Part of the Organic Chemistry Commons 
Recommended Citation 
Lookadoo, Maggie Sparks, "Chemical Investigations of Diabetes Mellitus, Malaria, and Castrate-Resistant 
Prostate Cancer. " Master's Thesis, University of Tennessee, 2015. 
https://trace.tennessee.edu/utk_gradthes/3551 
This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and 
Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE: 
Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu. 
To the Graduate Council: 
I am submitting herewith a thesis written by Maggie Sparks Lookadoo entitled "Chemical 
Investigations of Diabetes Mellitus, Malaria, and Castrate-Resistant Prostate Cancer." I have 
examined the final electronic copy of this thesis for form and content and recommend that it be 
accepted in partial fulfillment of the requirements for the degree of Master of Science, with a 
major in Chemistry. 
Shawn R. Campagna, Major Professor 
We have read this thesis and recommend its acceptance: 
Tessa R. Calhoun, Michael D. Best 
Accepted for the Council: 
Carolyn R. Hodges 
Vice Provost and Dean of the Graduate School 
(Original signatures are on file with official student records.) 
 
 








A Thesis Presented for the 
Master of Science 
Degree 






































I would like to thank my advisor Dr. Shawn Campagna for mentoring me 
throughout my graduate career and helping me to grow as a scientist.  I would also like 
to thank my lab members Dr. Hector Castro, Stephen Dearth, Carson Prevatte, Abigail 
Farmer, Brandon Kennedy, Allen Bourdon, Eric Tague, and Caleb Gibson for all of their 
advice, encouragement and friendship. I would also like to thank Dr. Amanda May for 
teaching me so much my first year working in the lab. I am incredibly grateful for all of 
the fond memories I have from working in the Campagna lab. Thank you to my 
committee members Dr. Tessa Calhoun, and Dr. Mike Best for your encouragement, 
support, and time. I also want to thank my family and friends for their love and support 















This work studies a variety of molecules and the systems they are involved in to 
further understand disease and treatment of diabetes mellitus, malaria, and castrate 
resistant prostate cancer. The first system studied, diabetes mellitus, involves synthesis 
of 5 different steroidal compounds, while the other two systems, malaria and castrate-
resistant prostate cancer, apply mass spectrometric-based untargeted metabolomics to 
study both known metabolites and unknown spectral features. 
Diabetes mellitus is a result of the dysfunction and death of islet beta cells 
caused by the transcription of pro-inflammatory cytokines resulting in reduced insulin 
secretion and uncontrollable blood glucose levels. Glucocorticoids can reduce 
inflammation at the transcriptional level preventing islet beta cell destruction and could 
be applied to aid in pancreatic transplants. Five glucocorticoids, 3 differently acylated 
mercapto hydrocortisone derivatives and 2 arylpyrazole mercapto hydrocortisone 
derivatives were synthesized and fully characterized to be used in bioassays to 
determine efficacy complementing previous work from our lab.1 
Untargeted mass spectrometric based metabolomics, using ultra performance 
liquid chromatography with an Orbitrap mass spectrometer was applied to study both 
malaria and castrate-resistant prostate cancer.  This allowed for the acquisition of full 
scan data so that known metabolites, as well as unknown spectral features can be used 
for metabolic pathway and statistical analyses. 
Recently, resistance to malaria has been observed as being influenced by gut 
microbiota indicating an unknown metabolite(s) transported between tissues is 
responsible for this change. Using our untargeted mass spectrometric based 
 v 
metabolomics approach unknown features were analyzed for plasma, cecum and small 
intestine samples for resistant and susceptible mice infected with Plasmodium yoelii. 
Exhibiting large significant fold-changes in concentration between resistant and 
susceptible mice, 8 spectral features were identified, and molecular formulae predicted 
by m/z and isotope analysis.   
Zyflamend, a dietary supplement consisting of herbal and spice extracts in olive 
oil, when taken along with hormone depravation therapy has shown to reduce prostate 
cancer growth twice as fast as hormone depravation therapy alone.2 By applying our 
untargeted UPLC-MS based metabolomics, changes in metabolomes of both humans 
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The relationship between chemistry and biology is complex, involving many 
different reactions and systems that change and modify phenotypes that influence 
disease. By studying and modifying the small molecules involved in these systems, the 
treatment of diseases can be greatly advanced.  The diseases studied and discussed 
are diabetes mellitus, malaria, and castrate-resistant prostate cancer. 
Chapter 2 discusses, diabetes mellitus, which affects around 9% of the 
population (type 1 and 2), is caused by the dysfunction of islet beta cells and their ability 
to produce insulin.1, 3 Damage of these islet beta cells is induced by inflammation; 
however, treatment with glucocorticoids as anti-inflammatories can directly inhibit insulin 
secretion. Synthesizing a molecule that is capable of reducing inflammation without 
impairing insulin secretion would prove to be advantageous with advancing the 
treatment of diabetes. Therefore, the synthesis and characterization of 5 different 
glucocorticoids that will provide a molecule or provide insight on structure activity 
relationships between the molecule and proteins it binds with, to provide an anti-
inflammatory allowing for healthy pancreatic transplantations for patients with diabetes. 
Chapter 3 introduces metabolomics, that is the platform of how these diseases in 
the subsequent chapters will be studied. Using ultra performance liquid chromatography 
coupled with an Orbitrap mass spectrometer allows for high resolution and full scan 
data to be acquired.  This chapter discusses the advantages, and how data is managed, 
and interpreted after acquired, allowing us to make observations about changes in the 
metabolome in response to change. 
 3 
Chapters 4 and 5 discuss how our metabolomics platforms were used to 
annotate changes in metabolome studying malaria and prostate cancer. The malaria 
study (Chapter 4) compared unknown spectral features in malaria resistant and malaria 
susceptible mice. Those features shown to be statistically different in concentration 
between susceptible and resistant phenotypes are analyzed to determine molecular 
formula. This uses metabolomics to study an observed difference in phenotype of a 
biological sample and understand what is the underlying cause.  
Chapter 5 studies the metabolic changes in biological samples when treated with 
Zyflamend, or a control study (olive oil) to determine the change in relative 
concentration of known metabolites and unknown spectral among various different 
tissue types, plasma, adipose, liver, and skeletal muscle in mice, as well as plasma in 
humans. So whereas, chapter 4, a difference is observed and the metabolites are 
searched in order to identify a particular compound that could be causing this 
difference; in chapter 5, a treatment in set in place to observe the overall changes 




Chapter 2:  Novel Glucocorticoids to Improve Therapies for Reducing 
























Because of national health concerns with rising rates of individuals diagnosed 
with diabetes mellitus, there has been an outcry for possible solutions to aid in treating 
and curing this disease.3 Glucocorticoids, after prolonged treatment, have been known 
to induce diabetes mellitus by altering islet beta cell health and permanently reducing or 
eliminating insulin production.4-7 Previous work in our lab in collaboration with Dr. Jason 
Collier at the Pennington Biomedical Research Institute in Baton Rouge, LA has 
recently provided a hydrocortisone derivative synthesized in our lab, that transrepresses 
pro-inflammatory genes but does not inhibit insulin secretion.8 This molecule and 
subsequent analogues show promise as anti-inflammatories allowing for transplantation 
of an insulin secreting, healthy pancreas. Mercapto hydrocortisone derivative steroids, 
with varying acyl substitutions, acetyl, hexanoyl, and benzoyl analogues, as well as 
mercapto hydrocortisone derivatives modified with an arylpyrazole functional group 
were synthesized and fully characterized for testing in bioassays to determine efficacy 











As of 2014, 29.1 million people in the United States, 9.3% of the population, 
suffer from type 1 or type 2 diabetes mellitus.3 Type 2 diabetes mellitus is a metabolic 
disorder brought about primarily by obesity but other factors such as a diet high in fat, 
lack of exercise, and genetics, which can play major roles in the onset of this disease.9 
Type 1 diabetes mellitus is an autoimmune disorder where insulin-secreting cells are 
destroyed by the immune system.10-12 The initial cause of this internal destruction is 
unknown, but pro-inflammatory cytokines IL-1β and γ-IFN are known to signal for NFκB 
pathways leading to dysfunction and death of islet beta cells.13, 14 Inducible nitric oxide 
synthase (iNOS) is one of the inflammatory enzymes induced by IL-1β, which allows for 
the accumulation of nitric oxide in cells and decreases viability of islet beta cells.11, 13, 15 
Chemokines, CXCL9 and CXCL10, which are secreted when the beta cells are 
inflamed, signal for T cells to respond, infiltrate and destroy the cells.16 Glucocorticoids 
(GCs) can be used to transrepress those genes to prevent islet beta cell destruction.6, 17 
Because these are dysfunctions at the genomic level, it is advantageous to treat this 
disease by modulating genomic expression.  Glucocorticoids (GCs) can be used to 
transrepress those genes to prevent islet beta cell destruction.6, 17 
Glucocorticoids are a family of steroidal compounds that can be naturally derived 
from cholesterol and produced in the adrenal glands that mainly bind to the 
glucocorticoid receptor (GR), reduce inflammation and alter metabolism.7, 18 Once the 
GC binds to the GR, as a unit, the complex translocates from the cytosol into the 
nucleus where the complex can then activate the glucocorticoid response element that 
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initiates or inhibits the transcription of specific sequences of DNA acting as a 
“transrepressor” or a “transactivator”.4, 7  
While GC treatments are advantageous as effective anti-inflammatories (GCs are 
active in many different tissue types), treatments are often associated with a variety of 
side effects including the disruption of beta cell function, or glucocorticoid-induced 
diabetes, promote abdominal obesity, and osteoporosis.4, 6, 19 Discovery of a GC 
capable of transrepressing pro-inflammatory genes without reducing insulin secretion 
will advance treatment of diabetes by allowing the transplantation of a pancreas that 
remains healthy and functional. 
Previously this year, our lab in collaboration with Dr. Jason Collier at the 
Pennington Biomedical Research Institute in Baton Rouge, LA, published work studying 
two specific glucocorticoids as potential drugs to be used to aid with difficulties of 
pancreatic transplants.  Those mercapto steroids, MS4 and MS6, shown in Figure 1, are 
compared to dexamethasone (an anti-inflammatory benchmark that inhibits insulin 
production), and showed to decrease transcription of pro-inflammatory cytokines that 
cause dysfunction of islet beta cells.1 As concentrations of dexamethasone, MS4, and 
MS6 are increase, indicated in log10 scale in Figure 1(a), the response of IL-1β is 
significantly decreased. Glucocorticoid, MS4, particularly showed promise as it 
decreased inflammation but did not impair insulin secretion in response to glucose 
stimulation shown in Figure 1(b) in human and mice cells.1 These data encourage 
further study into derivitizations similar to MS4 to further investigate GC structure 




Figure 1. Glucocorticoids dexamethasone, MS4, and MS6 and their responses for (a). 
IL-1β at varying log10 scale concentrations and (b). insulin secretion after 5.6 and 16.7 

















Building upon this previous work, 5 different hydrocortisone derivatives were 
synthesized and fully characterized.  Thiobenzothiazole modified hydrocortisone 
molecules were synthesized (MS4 as the parent molecule), providing 3 different 
acylation substitutions allowing for a small functionalized group, the acetyl analogue, a 
longer carbon chain, the hexanoyl analogue, as well as a benzoyl analogue, shown in 
Figure 2. 
 
Figure 2. Thiobenzothiazole hydrocortisone derivatives functionalized by different acyl 
chains: an acetyl analogue (a), a hexanoyl analogue (b), and a benzoyl analogue (c). 
 
 
Another family of GCs was synthesized and fully characterized combining the 
modification of the mercapto hydrocortisone steroid with an arylpyrazole functional 
group and continuing to modify functionalization with the substitution of a furoyl 
analogue, shown in Figure 3 a-b. Implementation of arylpyrazole functionality has 
shown to produce GCs that selectively modulate transactivational properties.20 These 
molecules are much larger and provide different electronic effects to study with how 
these molecules bind to the GR and what effects may be observed as a result. 
 
(a).  (b).  (c).  
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Synthesis of Mesylated Hydrocortisone (2) 
Hydrocortisone (0.1923 g, 0.531 mmol) was dissolved in 10 mL dichloromethane 
(DCM).  To this solution was added, N,N-diisopropylethylamine (DIPEA) (720µL, 4.13 
mmol) followed by mesthanesulfonyl chloride (64 µL, 0.827 mmol) and the reaction was 
allowed to stir at room temperature (shown in Scheme 1).  The reaction was monitored 
for completion by thin layer chromatography (TLC) and was stopped after approximately 
8 hours and concentrated in vacuo producing a yellow oil.  The oil was then re-dissolved 
in DCM washed with a saturated solution of sodium bicarbonate then washed twice with 
brine, dried with magnesium sulfate, filtered and concentrated in vacuo yielding a yellow 
crystalline product (2) in 95% yield. 
(a). (b). 
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Synthesis of Mercapto Hydrocortisone (3) 
 The crude product (2) was used for the substituting the mesylate with a 
mercaptobenzothiazole.  Mesylated hydrocortisone (2) (0.0760 g, 0.173 mmol) was 
dissolved in approximately 20 mL of acetone.  To this solution was added potassium 
carbonate (0.3178 g, 2.30 mmol) and 2-mercaptobenzothiazole (0.0796 g, 0.476 mmol).   
The reaction was allowed to reflux for 2 hours then filtered through a silica pad 
and concentrated.  The thiobenzothiazole-hydrocortisone (3) was then purified by 
column chromatography using 40% ethyl acetate in hexanes providing a purified 











cyclopenta[a]phenanthren-17-yl acetate (4a) 
To produce the acetyl analogue, (+)-(11S,17R)-17-(2-(benzo[d]thiazol-2-
ylthio)acetyl)-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate (4a, Figure 1), the purified 
mercapto hydrocortisone 3 (111.8 mg, 0.218 mmol) was then dissolved in 
approximately 15 mL of DCM at 0° C.  To the solution was added 4-
dimethylaminopyridine (35.6 mg, 0.291 mmol) followed by acetic anhydride (36 µL, 
0.381 mmol).  The reaction was allowed to slowly warm to room temperature and was 
allowed to stir for 15 hours.  After the reaction was complete, the solution was washed 3 
times with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to 
produce and off-white solid.  The solid was then purified by column chromatography 
using 0.5% methanol in dichloromethane to elute the product 4a as a white solid in 28% 
yield. Rf=0.59, 9:1 CH2Cl2:MeOH; mp 221° C; 
1H NMR (500 MHz, CDCl3) δ 7.91(d, J= 
8.17 Hz, 1H), 7.78(d, J= 7.94 Hz, 1H), 7.44(t, J= 7.22 Hz, 8.06 Hz, 1 H), 7.34(t, J= 7.36 
Hz, 7.87 Hz, 1H), 5.70(s, 1H), 4.69 (d, J= 16.98 Hz, 1H), 4.53(s, 1H), 4.42 (d, J= 17.01 
Hz, 1H), 3.01 (t, J= 15.53 Hz, 9.97 Hz, 1H), 2.50, (m, 6H), 2.24 (s, 3H), 1.84 (m, 10H), 
1.46 (s, 3H), 1.12 (m, 2H), 1.04 (s, 3H); 13C NMR (500 MHz, CDCl3) δ 199.36, 
171.62.171.60, 170.98, 168.98, 161.61, 126.54, 122.47, 122.46, 121.24, 120.74, 
110.15, 95.66, 68.23, 55.81, 52.58, 46.87, 40.27, 40.02, 39.20, 35.00, 33.84, 32.62, 
31.97, 31.47, 31.15, 23.89, 21.28, 21.00, 16.69; IR 3449.04, 2929.21, 1726.96, 
1658.45, 1428.38, 1368.25, 1240.04, 1000.56, 865.59, 757.29, 724.95 cm-1; HRMS-
 13 
DART (m/z): [M+H]+ calculated for C30H36NO5S2
+, 554.1990 found at 554.20002; [σ]D
21 





cyclopenta[a]phenanthren-17-yl hexanoate (4b) 
To produce the hexanoyl analogue, (+)-(11S,17R)-17-(2-(benzo[d]thiazol-2-
ylthio)acetyl)-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl hexanoate (4b, Figure 2), the 
purified thibenzothiazole-hydrocortisone 3 (106.6 mg, 0.208 mmol) was dissolved in 
approximately 15 mL of DCM at 0º C.  To the solution was added 4-
dimethylaminopyridine (36.9 mg, 0.302 mmol) followed by hexanoyl chloride (46 µL, 
0,329 mmol) and allowed to slowly warm to room temperature and was allowed to stir 
for 15 hours.  After the reaction was complete, the solution was washed 3 times with 
brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to produce a 
yellow oil.  The oil was then purified by column chromatography using 1% methanol in 
dichloromethane to elute the product 4b as a white solid in 39.3% yield.  Rf = 0.51 9:1 
CH2Cl2:MeOH; mp 85° C; 
1H NMR (500 MHz, CDCl3) δ 7.83 (d, J= 8.62 Hz, 1H), 7.74(d, 
J= 8.44 Hz, 1H), 7.42(t, J= 7.25 Hz, 7.05 Hz, 1H), 7.31 (t, J= 7.32 Hz, 6.84 Hz, 1H), 
5.71 (s, 1H), 4.55 (d, J=16.79, 1H), 4.52(s, 1H), 4.37(d, J= 16.83 Hz, 1H), 2.98 (m, 1H), 
2.48 (m, 2H), 2.36 (m, 3H), 2.19 (m, 4H), 2.06 (m, 3H), 1.93 (m, 6H), 1.64 (m, 2H), 1.55 
(s, 2H), 1.46 (s, 3H), 1.32 (m, 10H), 1.04 (s, 3H), 0.88 (m, 4H); 13C NMR (500 MHz, 
CDCl3) δ 199.42, 199.20, 173.61, 171.79, 165.63, 152.76, 135.54, 126.03, 124.36, 
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122.41, 121.24, 121.12, 95.36, 68.14, 55.89, 52.62, 46.98, 41.64, 40.17, 39.18, 34.97, 
34.38, 33.81, 32.63, 31.95, 31.36, 31.09, 24.44, 23.80, 22.28, 21.00, 16.75, 13.89; IR 
3461.69, 2931.63, 1711.58, 1659.25, 1429.82, 1285.13, 1101.68, 999.85, 714.89 cm-1; 
HRMS-DART (m/z): [M+H]+ calculated for C34H44NO5S2
+, 610.2616 found at 610.25931; 
[σ]D




cyclopenta[a]phenanthren-17-yl benzoate (4c) 
To produce the benzoyl analogue, (+)-(11S,17R)-17-(2-(benzo[d]thiazol-2-
ylthio)acetyl)-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl benzoate ( 4c, Figure 3), the 
purified thibenzothiazole-hydrocortisone 3 (113.0 mg, 0.221 mmol) was dissolved in 
approximately 15 mL of DCM at 0° C.  To the solution was added 4-
dimethylaminopyridine (29.0 mg, 0.237 mmol) followed by benzoyl chloride (31µL, 0.267 
mmol) and allowed to slowly warm to room temperature and was allowed to stir for 15 
hours.  After the reaction was complete the solution was washed 3 times with brine, 
dried with magnesium sulfate, filtered, and concentrated in vacuo to produce and off-
white solid.  The solid was then purified by column chromatography using 1% methanol 
in dichloromethane to elute the product 4c as a white solid in 38.2% yield.  Rf= 0.59 9:1 
CH2Cl2:MeOH; mp 124° C; 
1H NMR (500 MHz, CDCl3) δ 8.00 (d, J= 1.15 Hz, 2H), 7.78 
(dd, J= 8.11 Hz, 8.55 Hz, 2H), 7.63 (t, J= 7.47 Hz, 8.73 Hz, 1H), 7.48 (t, J= 8.11 Hz, 
7.53 Hz), 7.39 (t, J= 7.3 Hz, 9.32 Hz, 1H), 7.30 (t, J= 8.06 Hz, 8.29 Hz, 1H), 5.73 (s, 
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1H), 4.60 (d, J= 17.00 Hz, 1H), 4.57 (s, 1H), 4.40 (d, J= 17.02 Hz, 1 H), 3.13 (m, 1H), 
2.53 (m, 2H), 2.39 (m, 2H), 2.26 (m, 2H), 2.17 (m, 2H), 2.01 (m, 3H), 1.87 (m, 2H), 1.50 
(s, 3H), 1.25 (m, 2H), 1.16 (m, 2H), 1.11 (s, 3H); 13C NMR (500 MHz, CDCl3) δ 199.38, 
198.89, 171.63, 166.11, 165.59, 152.69, 135.57, 133.82, 129.72, 129.47, 128.69, 
125.99, 124.34, 122.54, 121.22, 96.23, 71.59, 69.22, 56.16, 53.24, 47.32, 45.12, 41.42, 
40.63, 39.24, 35.06, 33.86, 32.63, 31.95, 31.50, 31.21, 23.91, 21.01, 16.86, 14.19; IR 
3452.71, 2931.40, 1711.58, 1659.25, 1429.82, 1285.13, 1101.68, 999.85, 714.89 cm-1; 
HRMS-DART (m/z): [M+H]+ calculated for C35H38NO5S2
+, 616.2147 found at 616.21544; 
[σ]D
21 +81.5 (c 1.00, CH2Cl2). 
 
Synthesis of Mercapto-Arylpyrazole Hydrocortisone Derivative 
A similar synthesis to provide the arylpyrazole moiety and subsequent analogue 
begins with an arylpyrazole hydrocortisone derivative, (5) synthesized by a previous lab 
member, Dr. Amanda May. This synthesis involves the mesylation of the primary 
alcohol to substitute with a thiobenzothiazole to provide the mercapto arylpyrazole 
hydrocortisone derivative shown in Scheme 2. Steroid 7 is then further modified by 
acylating at the tertiary alcohol providing steroid 6.  
 
Synthesis of mesylated arylpyrazole hydrocortisone derivative 
Steroid 5 (119.0 mg, 0.2476 mmol) was dissolved in approximately 15 mL of 
DCM.  To the solution was added N,N-diisopropylethylamine (DIPEA) (33 µL, 1.89 
mmol) followed by mesyl chloride (30 µL, 0.388 mmol) at room temperature and allowed 
to stir for 9 hours.  The reaction was then concentrated in vacuo, redissolved in DCM, 
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washed with brine 3 times, dried with magnesium sulfate, then concentrated in vacuo.  
The product resulted in a yellow powder, steroid 6 in 70.2% yield.  
 
 






 The crude steroid 6 (97.1 mg, 0.1378 mmol) was dissolved in approximately 45 
mL of Acetone.  To the solution was added potassium bicarbonate (24.01 mg, 1.737 
mmol) followed by 2-mercaptobenzothiazole (58.1 mg, 0.3474 mmol), and the reaction 
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was allowed to reflux.  After 2 hours of reflux, the reaction was then cooled to room 
temperature and filtered over a pad of silica then concentrated in vacuo producing a 
yellow oil.  The oil was then purified by column chromatography using 30% ethyl acetate 
in hexanes yielding steroid 7 in 53.4% yield. Rf= 0.75 9:1 CH2Cl2:MeOH; mp 159° C; 
1H 
NMR (500 MHz, CDCl3) δ7.76 (dd, J= 8.14, 7.95 Hz, 2H), 7.47 (m, 2H), 7.41 (t, J= 7.49 
Hz, 7.60 Hz, 1H), 7.49 (t, J= 7.60, 7.43 Hz, 1H), 7.18 (t, J= 8.4, 8.55 Hz, 2H), 6.07 (s, 
1H), 5.03 (d, 15.12 Hz 1H), 4.55 (s, 1H), 3.31 (d, 15.13 Hz, 1H), 3.04 (d, J= 15.27 Hz, 1 
H), 2.85 (t,13.94, 13.52 Hz, 1H), 2.72 (d, 15.37 Hz, 1H), 2.52 (t, 14.77, 14.76 Hz, 1H), 
2.39 (d, 16.53 Hz, 1H), 2.30 (d, 14.36 Hz, 1H), 2.02 (m, 4H), 1.71 (d, 15.52 Hz, 1H), 
1.46 (m, 4H), 1.34 (s, 3H), 1.26 (m, 8H), 0.98 (s, 3H), 0.88 (m, 2H); 13C NMR (500 MHz, 
CDCl3) δ 206.70, 167.32, 152.95, 151.69, 137.31, 135.02, 126.35, 125.66, 124.80, 
121.32, 120.51, 116.29, 115.98, 113.86, 107.22, 91.21, 68.52, 56.57, 52.35, 46.81, 
41.45, 40.61, 36.68, 36.65, 34.75, 33.83, 33.81, 32.11, 29.69, 29.35, 23.97, 22.40, 
17.86; IR 3345.99, 2925.09, 1712.09, 1514.14, 1429.68, 1228.82, 1116.06, 1004.05, 
840.81, 734.40 cm-1; HRMS-ESI (m/z): [M+H]+ calculated for C35H36FN3O3S2
+, 630.2216 
found at 630.22157; [σ]D




tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl furan-2-carboxylate (8) 
 The purified steroid 7 (58.4 mg, 0.0927 mmol) was dissolved in approximately 15 
mL of DCM.  To the solution was added N,N-dimethylaminopyridine (DMAP) (13.8 mg, 
0.1130 mmol) followed by furoyl chloride (10.3 µL, 0.104 mmol) at room temperature 
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and allowed to stir.  After 24 hours, the reaction was washed with brine 3 times, dried 
with magnesium sulfate, filtered, and concentrated in vacuo. The product was then 
purified using 1% methanol in DCM and collected as a yellow solid in 21.8% yield. Rf= 
0.82 9:1 CH2Cl2:MeOH; mp 151° C; 
1H NMR (500 MHz, CDCl3) δ 7.70 (dd, J= 8.07, 
7.91 Hz, 2H), 7.61 (s, 1H), 7.44 (m, 3H), 7.39 (t, J= 8.12, 7.20 Hz, 1H), 7.31 (d, J= 6.86 
Hz, 1H), 7.24 (d, J= 3.52 Hz, 1H), 7.16 (t, J= 8.43, 8.59 Hz, 2H), 6.55 (dd, J= 1.7, 1.48 
Hz, 1H), 6.09 (s, 1H), 4.6 (d, J= 17.04 Hz, 2 H), 4.38 (d, J= 17.07 Hz, 1H), 3.10 (m, 2H), 
2.79 (d, J= 15.26 1H), 2.40 (m, 6H), 2.04 (m, 7H), 1.35 (s, 3H), 1.10 (s, 3H); 13C NMR 
(500 MHz, CDCl3) δ 198.57, 165.55, 158.08, 152.68, 147.04, 144.07, 137.73, 136.73, 
135.57, 125.97, 125.36, 125.29, 124.30, 121.22, 121.08, 119.28, 116.08, 115.90, 
113.71, 112.09, 107.58, 96.60, 68.26, 56.68, 53.16, 47.39, 41.42, 40.44, 33.94, 32.15, 
32.04, 31.66, 31.38, 31.11, 30.13, 29.96, 29.64, 23.85, 22.45, 16.82; IR 3405.91, 
2923.63, 1717.95, 1463.07, 1384.29, 1309.29, 1228.18, 1175.94, 1108.45, 999.36, 
839.58, 759.73cm-1; HRMS-ESI (m/z): [M+H]+ calculated for C40H39FN3O5S2
+, 724.2270 
found at 724.22705; [σ]D
21 +64.7 (c 1.00, CH2Cl2). 
 Novel mercapto steroids 4(a-c) were synthesized by adapting a previous 
synthesis using commercially available hydrocortisone (1) as starting material, as 
shown in Scheme 1.21 All reactions were completed in an inert atmosphere using dry, 
reagent grade solvents unless otherwise specified. Synthesis of the arylpyrazole 
mercapto hydrocortisone followed preparation methods published by Bijui et al in 2012 
to provide the parent structure for the novel furoyl arylpyrazole mercapto hydrocortisone 
derivative shown in Scheme 2.22  
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Determination of Glucocorticoid Efficacy and Biological Assays 
In order to test these molecules a series of biological assays are employed to 
observe inflammatory capabilities and their impact on insulin production in Beta cells.  
Beta cells from rats, mice, and humans are used for these experiments.  Glucose 
stimulated insulin responses are measured according to a previous method and 
compared to the dexamethasone standard.23, 24 Dexamethasone is known to inhibit 
insulin secretion in mice completely and reduce human insulin secretion by 59%.1   
Toxicity towards beta cells is also measured using MTS and adenylate kinase 
(ADK) assays, over 48 hours. Cultures of 832/13 cells are grown in exposure to various 
concentrations of the steroids, decreases in MTS and increases in ADK cause damage 
to beta cells, depending on how these glucocorticoids change MTS and ADK 
concentrations will give insight to their toxicity.1, 10, 25 Transactivation and 
transrepression can be observed and analyzed using Luciferase assays (insulin-
promoter luciferase reporter and NF-κB genes), enzyme linked immunosorbent assay 
(ELISA), and real time PCR analysis1, 8, 14.  In collaboration with Dr. Jason Collier, these 





 In efforts to gain more insight on structure activity relationships between the 
glucocorticoid ligand, the glucocorticoid receptor, and the glucocorticoid response 
element, 5 new hydrocortisone derivatives have been synthesized and fully 
characterized.  These molecules will help in defining what functional groups provide a 
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complex that is capable of dissociating between transrepression of pro-inflammatory 
cytokines and maintain insulin secretion in response to glucose.  The biological assays 
to determine this efficacy are underway. 
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Metabolomics is a relatively new field attempting to observe changes in biological 
samples by studying the metabolome, which consists of thousands of small molecules 
involved in cellular processes. Genomics and proteomics also monitor the actions of a 
cell but show what the cell is trying to do, or what the cell will do.26, 27 Metabolomics 
allows us to take a “snapshot” of what the cell is doing at that moment.26, 28 In particular, 
metabolomics takes into account post-translational modification.29-31 
Nuclear magnetic resonance (NMR), Fourier transform infrared spectroscopy 
(FTIR), and direct infusion mass spectrometry (DIMS) are common metabolomics 
techniques and provide a “fingerprint” for many biological samples.29, 32, 33 These 
techniques are popular because they require little sample preparation and provide 
spectra characterizing the entire sample. Unfortunately for these techniques separation 
of molecules is rarely applied and the spectra produced are difficult to distinguish 
differences between individual metabolites and have higher limits of detection than GC-
MS or LC-MS methods.34  
Mass spectrometry based methods are popular among scientists to collect large 
datasets to characterize the metabolome of various different biological systems.  Gas 
chromatography coupled with mass spectrometry (GC-MS) is a commonly used mass 
spectrometric technique in metabolomics and provides efficient separation but, because 
of necessary sample derivitizations leading to further ambiguity in parent mass, GC-MS 
is not the better option when attempting to determine unknown metabolites.35, 36  
Ultra-performance liquid chromatography (UPLC) provides the desired 
separation, without derivitizations and can be coupled with high-resolution mass 
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spectrometry allowing for acquisition of large datasets.37, 38 Accuracy and low detection 
limits provided by an Exactive Plus Orbitrap Mass Spectrometer are utilized in this 
experiment to identify accurate masses of the metabolites extracted from only a few 
milligrams of tissue.39-41 Using this method allows for the collection of full-scan data so 
that all extracted and ionized metabolites are observable at low detection limits and 
provide a much more inclusive metabolic profile for diverse types of biological 
samples.27, 39, 40 This provides a novel approach by using untargeted mass 
spectrometry-based metabolomics to search for metabolites or biomarkers that have the 
possibility of playing key roles in treating many different diseases. 
When such large datasets are required, new and different techniques are 
required to observe and identify these changes amongst populations. Some useful 
techniques for managing such data are principle component analysis (PCA) and partial 
least squares-discriminant analysis (PLS-DA). These tools allow for the comparison of 
variance among data sets so that samples causing the most variance among 
populations of sample types can be identified.42 PLS-DA is a common technique in 
metabolomics and other –omics sciences when the number of data points is much 
larger than the number of samples because it optimizes separation between sample 
types by finding a linear subset of the data and reducing the number components. 33, 42 
Collinear noisy data presented in this fashion allows trends in populations and 
differences among phenotypes to be accentuated.  
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Chapter 4: A Mass Spectrometry-Based Approach to the Identification of 























Malaria is a disease caused by various species of Plasmodium is carried and 
transmitted by the Anopheles mosquito and causes the deaths of hundreds of thousand 
worldwide each year. Because the disease is most prevalent in developing countries 
where treatment is unaffordable for many, a cost-effective method of treatment is 
desirable. Through collaborative efforts with Dr. Nathan Schmidt in the Microbiology and 
Immunology Department at the University of Louisville and Dr. Steven Wilhelm from the 
Microbiology Department at the University of Tennessee Knoxville, it has been recently 
discovered that a specific bacterial biome within the gut of a mouse displays a 
relationship where the bacteria provide resistance to the malaria parasite, Plasmodium 
yoelii.  
With the disease residing in the blood but the resistance originating in the gut, we 
hypothesize that a small molecule or a group of small molecules produced by the 
bacteria permeate through tissues and provide resistance. Previous work, not yet 
published shows significant changes in concentrations of known metabolites involved in 
purine and pyrimidine metabolism, TCA and Urea cycles as well as the pentose 
phosphate pathway between resistant and susceptible mice. This project uses a mass 
spectrometry-based approach to the identification of unknown metabolites that provide 
resistance to the malaria parasite, Plasmodium yoelii, in mice. The unknown spectral 
features showed significant differences between resistant and susceptible mice and 
were mined for compounds showing large significant fold changes delivering a list of 8 
features and their respective molecular formulae predicted by m/z and isotope analysis. 
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Introduction 
Globally, an estimated 198 million people contracted malaria in 2013; of those an 
estimated 584,000 resulted in death with around 70% of those individuals being under 
the ages of 5.43 Most cases of malaria are found in developing countries near the 
equator where weather patterns provide optimal conditions for the Plasmodium and the 
Anopheles mosquito carrier, pest control is difficult, stagnant water is not always 
drained, and people often sleep exposed to the environment.43-45 Complications also 
arise because infected persons delay treatment by not seeking out medical attention or 
are unable to until the disease has progressed.46, 47 High mutation rates in both the 
Anopheles mosquito and the Plasmodium parasite itself render medication less 
effective; and without an effective vaccine available, a reasonable and more beneficial 
form of treatment is of upmost importance.48  
Genetically similar C57BL/6 mice were purchased from different vendors, the 
National Cancer Institute (NCI) and Jackson Laboratories (JAX). All mice were infected 
with Plasmodium yoelii, a malarial parasite in mice, and different phenotypes of 
parasitemia were observed.  Mice from the National Cancer Institute exhibited 
significantly higher levels of parasitemia than mice from the Jackson Laboratories, 
which showed resistance and remained healthier overall.  
 Cecal contents from susceptible mice were transplanted into resistant mice then 
infected with Plasmodium yoelii, and those mice, which were previously resistant, 
exhibited susceptibility. The same was done for susceptible mice, which received 
transplants of cecal contents from resistant mice, then infected with Plasmodium yoelii, 
were observed to attain resistance against parasitemia. To further test these findings, 
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germ-free mice also received fecal transplants from susceptible or resistant mice and 
were observed as susceptible after receiving transplants from NCI mice, and resistant 
after receiving transplants from JAX mice. Bacterial communities within the gut of the 
different mice were identified and compared determining that there were significant 
differences between JAX and NCI mice. Among those different bacterial communities, 
Lactobacillus and Bifidobacterium were identified to reduce parasitemia when mice 
were treated with yogurt cultured with these bacteria.  
With no direct contact between the Plasmodium, which resides in the blood, and 
the bacteria providing resistance in the gut, this leads us to hypothesize that a small 
molecule(s) is passively transported between tissues through the epithelial tissues of 
the gut and into the bloodstream to alter susceptibility of the mouse host to the disease, 
as depicted in Figure 4. This would allow for the microbiota of the gut to directly have an 
effect without being in direct contact with the Plasmodium.  
Figure 4.  Movement of small molecules from gut small intestines and/or cecum through 
epithelial tissue into the bloodstream and site of infection 
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An untargeted UPLC-mass spectrometric-based approach is used to collect all 
extracted and ionizable metabolites collected from both resistant and susceptible mice 
to probe for a single molecule or group of molecules that change phenotypic expression 
of parasitemia. Because the microbial communities providing resistance are in the gut, 
but the parasite resides in the blood, the molecule(s) we are searching for should be 
present in at least the plasma and cecum and/or small intestine.  
Previous work in our lab, no yet published showed significant changes in 
metabolites identified within the different tissues when compared between resistant and 
susceptible mice.  Some of the metabolites that showed changes in relative 
concentration were involved in purine metabolism, the TCA cycle, Urea cycle, pentose 
phosphate pathway, and pyrimidine metabolism 5(a).  There were also significant 
differences among populations of metabolites identified when analyzing by PLS-DA on 
when comparing resistant and susceptible mice for each individual tissue type (shown in 
Figure 5(b-d). To further investigate the metabolomes of resistant and susceptible mice, 
unknown spectral features were acquired and explored to provide molecular formulae 
for features that showed potential for causing resistance against malaria in mice. 
 
Materials and Methods 
Mass Spectrometric Metabolomics Method 
A population of 10 genetically similar C57BL/6 mice from different vendors, 
Jackson laboratories (malaria resistant) and the National Cancer Institute (malaria 
susceptible) were used for metabolic comparison.  All mice were injected with  
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Figure 5.  (a). Heat map of known metabolites comparing relative concentration 
between resistant and susceptible mice.  Brighter colors indicate more intense log2 
scale fold changes with red colors for metabolites of higher concentration in resistant 
samples and blue colors for metabolites lower in concentration relative to susceptible 
mice. Partial Least Squares-Discriminant Analysis for Jax (resistant) mice in blue and 
NCI (susceptible) mice in red for (b). plasma, (c). cecum, and (d). small intestines 







Plasmodium yoelii, a species causing malaria in mice, then plasma, cecum, and small 
intestine samples were collected from each mouse. 
Samples were frozen with liquid nitrogen and homogenized using a mortar and 
pestle. Samples were then weighed, placed into eppendorf tubes and extracted twice 
using an acidic acetonitrile extraction solvent (0.1% formic acid in 40:40:20 methanol, 
acetonitrile, water), aqueous layers were combined in a vial and dried under a flow of 
nitrogen, then re-suspended in HPLC-grade water.40 The samples were then separated 
by ultra performance liquid chromatography using gradient elution by mobile phase A 
(97:3 water, methanol, 10 mM tributylamine, and 15 mM acetic acid) and mobile phase 
B (methanol) on a 2.5 micron reverse phase, C18 column with a flow rate of 200 L/min.  
Samples were ionized by electrospray ionization (ESI) and analyzed by an Exactive 
Plus Orbitrap mass spectrometer and full scan data collected in negative ion mode.39  
Using MAVEN software, the extracted ion chromatogram is search for peaks that 
have an ion count of at least 105 ions.49 Peaks were then manually verified for good 
Gaussian peak distribution, large signal to noise ratios, and lack of signal in blanks. 
Because this method is searching for metabolites changing parasitemia caused by a 
parasite residing in the blood, peaks must also be biased to select only those that show 
those peak characteristics in the plasma samples. Peak areas for each metabolite were 
then normalized according to mass of each cecum and small intestine sample analyzed. 
Plasma samples were normalized according to starting volume of plasma (25 μL). 
Isotope analysis of each feature is completed to determine charge multiplicity as 
well as carbon and nitrogen composition. Isotope peaks (12C peak and 13C peak) that 
are 1 mass unit away show that the molecule holds a -1 charged, while peaks 0.5 and 
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0.33 mass units away contain charges of -2 and -3 respectively. Isotope peaks for 15N 
and 13C are 0.998 and 1.003 mas units away respectively and peak intensities were 
used in comparison to the 12C peak to determine number of carbon and nitrogen atoms 
present for each feature.   
The natural abundance of 13C and 15N are 1.08% and 0.364% respectively, so if 
a metabolite shows isotope peaks that is 8.65 and 1.46% intensities compared to the 
12C peak, it can be predicted that molecule contains 8 carbon and 4 nitrogen atoms.50 
For this experiment, H2O, NH4
+, K+, Na+, ACN, Cl-, and CH3COO
-, are all suspected 
adducts because of possible presence in biological sample matrix, extraction solvents, 
or UPLC mobile phases and must be factored in for the calculation of each potential 
parent mass.51, 52 
 Xcalibur software was used to calculate different possible molecular formulae for 
each spectral feature. Formulae were collected for 2-electron ion m/z and containing 
carbon, hydrogen, nitrogen, oxygen, phosphorus, and sulfur atoms.  Formulae were 
then critiqued following the 7 golden rules for identifying unknown compounds 
developed in the Fiehn Lab at the University of California, Davis eliminating unrealistic 
compounds.51 
 
Results and Discussion 
Extracted Metabolite Candidates 
Following extraction and mass analysis, MAVEN software was used to process 
and automatically select peaks from the raw data.49 This identified over 55,000 different 
spectral features with a m/z and corresponding ion count.  To ensure good peak quality 
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by Gaussian distribution and large signal to noise ratio, peaks were manually screened 
from 55,000 selecting 181 features with high quality peaks in the plasma samples.  
Because the metabolite that could be interacting with the response to the parasite must 
be in the blood and at least one or both cecum and small intestine tissues, peaks that 
were in other tissues but not in the blood were discarded.   
A partial least squares – discriminant analysis (PLS-DA) was used to observe 
changes in metabolome for the resistant and susceptible mice across the different 
tissue types, plasma, cecum, and small intestine shown in Figure 6. This showed that 
the greatest variance among the tissues of the different mice showed greater difference 
between tissues, but were indistinguishable between resistant and susceptible mice.53  
Figure 6.  Partial Least Squares - Discriminant Analysis (PLS-DA) of unknown 
metabolites in resistant (Jackson Laboratories (JAX) and susceptible National Cancer 




PLS-DA was then applied to determine the variance between JAX and NCI mice 
for each tissue individually and was successfully able to discriminate between them 
(Figure 7).54 By applying an F-test to compare the significance of the variance among 
samples, it was determined that each tissue type showed significant variance with p 
values less than 0.0001 for each tissue type in the X1 variate.  This shows that the X1 
variate is sufficiently able to significantly distinguish between JAX and NCI mice, and 
that the variance observed between sample types is caused by a group of molecules. 
Features with m/z’s of 149.061, and 242.0141 were identified by PLS-DA as responsible 
for the most variance in plasma and cecum, and small intestine tissues respectively.  
Peak area ratios between JAX and NCI were clustered and arranged in a heat 
map, using Cluster and Java Treeview software programs, shown in Figure 8.55, 56 
Compounds of higher relative concentration in resistant mice (JAX) are shown in red, 
and compounds of lower relative concentration are shown in blue. Only features that 
showed a significant difference in fold change between resistant and susceptible mice 
were included in Figure 8. Criteria of a significant fold changes of 1.5 or greater has 
been set to limit the number of candidate features for further analysis so that a more 
manageable number of molecules can be examined. 
From these data, 8 different features are found to be statistically significant and 
have fold changes greater than 1.5 in the plasma and cecum or small intestine or both.  
Those features indicated by their observed m/z are shown in Table 1 with the fold 





Figure 7.  Partial Least Squares – Discriminant Analysis for individual tissue types of 


















Figure 8.  Heat map showing relative concentration of unknown 
metabolites between different tissue types from malaria resistant (J) 
and malaria susceptible (N) mice. (*** p   0.01, ** p  0.05, * p 0.1, 
- p     )  
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Table 1.  Fold-changes between malaria resistant and malaria susceptible mice.  
Molecules with no given fold change data were not statistically relevant for that sample. 
 
m/z J/N Plasma J/N Cecum J/N Small Intestine 
149.061 -4.3 -7.8 -2.2 
165.0575 2.1 1.9 - 
204.0683 -4.4 - -4.6 
224.025 0.5 3.2 1.9 
242.0141 4.4 3.4 3.9 
336.0727 9.6 - 5.2 
338.0879 5.8 - 4.8 
377.1822 -1.6 - -1.5 
*Fold changes are listed in Log2 scale 
 
 
Each of the 8 features was analyzed using m/z and isotopes for both 13C, and 
15N were used to match a feature with its molecular formula.  Many different possible 
atomic compositions including carbon, hydrogen, nitrogen, oxygen, sulfur, and 
phosphorus were generated using Xcalibur and included in the appendix.  Following the 
7 golden rules from the Feihn lab, eliminating molecular formula that exceed Lewis 
bonding rules and only including formulae that matched with carbon and nitrogen 
percentages, a final list of the top hits for molecular formulae were predicted for each of 














149.061 [M+H]- 150.0682 C9 H10 O2 1.3 9 
165.0574* [M+Cl-]- 131.0952 C6H13NO2 4.9 6 
204.0863 [M-2H+K+]- 167.1189 C7H5NO4 4.5 7 
224.025 [M-H+NH3]
- 208.0057 C7H4O2N4S 1.3 7 
336.0727 [M-H]- 337.0798 C15H15NO8 0 15 
338.0879 [M-H]- 339.0954 C15H17NO8 0 15 
377.1822 [M-H+]- 378.1895 C20H31N2OPS 0 20 
242.0141* [M+Cl-]- 208.05198 C8H9N4OP 5 8 
Only top hits that most closely match are listed 
* Indicates that an isotope peaks were observed for Cl 
 
Conclusions 
After full scan data acquisition, significant differences can be observed between 
resistant and susceptible mice. From these data 181 peaks features were detected and 
selected for in plasma samples across resistant and susceptible mice, after comparing 
peak areas to extract species of difference between resistant and susceptible mice, 8 
features were selected for features large significant fold changes in concentration 
between resistant and susceptible mice. After analysis of isotope peaks and m/z 
molecular formulae were predicted and analyzing providing a formula for each feature. 
For further analysis of each spectral feature, fragmentation data must be collected and 
examined.  
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Chapter 5:  A Metabolic Analysis of the Treatment of Prostate Cancer with 
























Dietary supplement, Zyflamend has been recently studied as an additional 
treatment for castrate-resistant prostate cancer.  Tumors treated using hormone 
depravation therapy and Zyflamend were observed as reducing in size twice as fast as 
tumors treated with HDT alone.2 This study shows how the metabolome is affected by 
using this dietary supplement as additional method of treatment for prostate cancer.   
Metabolites and unknown spectral features are collected for mice plasma, 
adipose, liver, and skeletal muscle tissue for both Zyflamend and control, placebo (olive 
oil), treated samples as well as human plasma samples collected at 0 and 8 weeks for 
Zyflamend treated and control patients. Significant changes in concentrations for 
metabolites involved in the TCA cycle and purine metabolism were observed in mouse 
plasma, adipose, and liver tissues as well as pyrimidine metabolism in mouse liver and 
adipose tissues after 4 weeks of treatment with Zyflamend. A partial least squares-
discriminant analysis showed differences in metabolism for all mice tissues for both 
known and unknown spectral features.  
Human plasma samples showed no significant differences among known 
metabolites but did show differences in 36 different unknowns after 8 weeks of 
treatment.  Mice and human plasma showed 5 unknowns in common that significantly 
changed after Zyflamend treatment exhibiting similar fold changes in relative 






Prostate cancer is one of the leading causes of cancer related deaths in men 
living in the United States.57, 58 This form of cancer is particularly difficult to identify and 
treat because of how the cancerous tissue grows in ribbon like structures throughout the 
prostate and often metastasizes quickly.58, 59 Prostate cancer proves to be the most 
difficult with diagnosis because there are no obvious symptoms, and once the tumor 
has metastasized, life expectancy beyond 5 years plummets to 31%.59 To prevent 
metastasis and provide earlier detection of prostate cancer, prostate-specific antigen 
(PSA) levels in blood are monitored.57, 60 An increase of PSA levels in blood suggests 
that the prostate is not functioning properly and is often associated, but not exclusively 
so, with prostate cancer.60-62 
Prostate cancer has high sensitivity to the hormone binding of the androgen 
receptor (AR), and it has been shown that by preventing a hormone to bind, the tissue is 
less capable of growing.57, 63 Prostate cancer is typically treated by hormone deprivation 
therapy (HDT), lowering testosterone levels in the blood (castration).63, 64 Though HDT 
does slow tumor growth, tumors can become castrate-resistant and are exceedingly 
difficult to treat.58 Zyflamend, a dietary supplement composed of ginger, curcumin, 
green tea, rosemary, thyme and other natural spices in olive oil has shown to, along 
with HDT, reduce cancer growth significantly in castrate-resistant tumors.64-66 The 
composition of Zyflamend has been highly characterized identifying 23 bioactive 
compounds identified and found in Zyflamend.67, 68 
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Materials and Methods 
Mice were fed a human equivalent dosage of Zyflamend (16 mg/day/mouse) in 
their food over the span of 4 weeks.  The control mice were given olive oil as a placebo.  
Blood samples were taken at the beginning of the trial (0 weeks) and at the end of the 
trial (4 weeks).  After the trial, mice were euthanized and liver, skeletal muscle, and 
adipose tissue were also collected.  For the human samples, patients with prostate 
cancer received either Zyflamend, or the placebo (olive oil) and blood samples were 
taken at the beginning of the trial (0 weeks) and again after 8 weeks.  
Mouse skeletal muscle, liver, and adipose tissues were frozen with liquid 
nitrogen, homogenized using a mortar and pestle, and samples of approximately 50 mg 
were used for extraction. The samples extracted twice using an acidic acetonitrile 
solvent (0.1% formic acid in 40:40:20, acetonitrile:methanol:water) at 4° C, vortexed and 
incubated at -20° C.  The aqueous layers were then combined, transferred into a vial, 
then dried under a flow of nitrogen.40 Once samples were dry, they were re-suspended 
in 300 μL HPLC grade water. Human and mouse plasma samples of 25 µL each were 
also extracted using the same acidic acetonitrile extraction solvent and method. The 
samples were then analyzed by the same UPLC-MS separations and detection method 
as previously described in Chapter 3.39  
Raw data was analyzed using MAVEN software to match m/z and retention times 
with previously characterized known metabolites selecting peaks with good signal to 
noise and Gaussian peak distribution.49 A list of 23 bioactive molecules known to be in 
Zyflamend was compiled using predicted m/z, but with unknown retention times in order 
to probe data for possible involvement of bioactive molecules in Zyflamend. Unknown 
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features were also collected by the same method as described in chapter 3, for plasma 
samples of both human and mice sample types.  All samples were normalized by mass 
or volume for plasma samples. 
 
Results and Discussion 
 This study examines the effects of adding a dietary supplement; normal dosages 
are used in order to observe a typical metabolic response in both humans and mice. 
Both known metabolites and unknown spectral features will be analyzed to gain a broad 
picture of how the metabolome is changing after treatment with Zyflamend. 
 
Known Metabolites 
A total of 99 different known metabolites were identified in at least one sample 
type of mouse adipose, skeletal muscle, liver, or plasma, or human plasma.  Among 
those 98 metabolites, only 58 showed to have statistically different relative 
concentrations when the Zyflamend treated samples were compared to the control 
group samples. A collection of 17 metabolites were seen to be significant in mouse 
adipose tissue, 1 in mouse skeletal muscle, 19 in mouse liver, 9 in mouse plasma 
collected at 0 weeks, 25 in mouse plasma collected at 4 weeks, and only 1 metabolite 
collected in human plasma at 0 weeks, shown in Figure 9.  There were no significantly 
different metabolites between Zyflamend treated humans and the placebo treated 
humans at 8 weeks.  
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 Those metabolites are depicted in a heat map (Figure 10), showing metabolites 
with a higher concentration in the Zyflamend treated samples in red and those with 
lower concentrations in blue. In adipose samples, fumarate, involved in the TCA cycle, 
and citruline, involved in the Urea cycle, were both observed as significantly lower in 
concentration in Zyflamend treated mice as opposed to the control mice (pathway maps 
generated using keg.jp in appendix).69   
 
Figure 9. Metabolites with significantly different concentrations between Zyflamend 
treated and control samples in each tissue type. 
 
In liver samples, citrate/isocitrate and cis-aconitate, involved in the TCA cycle, 
were observed as having significantly lower concentrations in Zyflamend treated mice.  
In plasma at the initial point of the trial (0 weeks) succinate was observed as having 
significantly higher concentrations in Zyflamend treated mice.  In plasma collected at the 
end of the 4 week treatment, cis-aconitate, involved in the TCA cycle, and arginine, 
involved in the Urea cycle, were observed as having significantly lower concentrations 
in Zyflamend treated mice. 
58 Significantly different 
metabolites 












98 total Metabolites 
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    Figure 10.  Heat map showing concentration ratios of Zyflamend to the control 
samples for all metabolites identified in mouse adipose, skeletal, and liver tissues, 
mouse plasma at 0 weeks and 4 weeks, and human plasma at 0 weeks and 8 weeks. 
(*** p   0.001, ** p  0.05, * p 0.1, - p     ) Grey boxes indicate that the metabolite 
was not found in that tissue. 
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Across tissue types in mice, 2 metabolites, inosine and xanthine, involved in 
purine metabolism, were seen to change significantly amongst plasma taken at 4 
weeks, liver, and adipose.  Inosine and Xanthine both showed a decrease in blood and  
adipose tissues, but was seen to increase in liver tissue.  Other metabolites, UMP, IMP, 
CMP, AMP, dGMP, xanthosine, hypoxanthine, cytidine, guanine, and guanosine, 
showed significant changes in relative concentration for Zyflamend and control plasma, 
liver and adipose tissue samples; however, not all metabolites were seen as significant 
in all tissue types, shown in Figure 11.  
Figure 11.  Heat map showing fold changes in concentration of metabolites involved in 
Purine metabolism in plasma, liver, adipose, and skeletal tissues in mice treated with 
Zyflamend relative to control mice. 
 
A partial least squares discriminant analysis is used to probe for trends in 
variation among samples (Figure 12) and shows that there are similarities among tissue 
type in regards to variation of metabolite concentration.  When comparing all 
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metabolites and all tissue types, samples are distinguishable among tissue type, but it is 
impossible to distinguish obvious differences of metabolomes between Zyflamend 
treated individuals and the control of the same tissue type and between human and  
Figure 12.  Partial Least Squares – Discriminant Analysis for all known metabolites 
detected in mouse adipose, liver, and skeletal tissue, mouse plasma at 0 weeks and 4 
weeks, and human plasma at 0 weeks and 8 weeks for both Zyflamend treated and 
control samples. 
 
mice plasma samples.  To observe changes further within an individual tissue type, 
PLS-DAs are performed on data of each tissue type and shown in Figure 13.  It can be 
noted through PLS-DA distribution of points for different sample types that metabolomes 
of mouse plasma from Zyflamend treated (4 weeks) and the control (4 weeks) groups 
are significantly different from one another (p value  0.01) and from the Zyflamend 
treated (0 weeks) and control (0 weeks), but the Zyflamend treated (0 weeks) and 
control (0 weeks) are not statistically different (p value > 0.1).  This same trend of 
separation in variance among known metabolites is observed for all mouse tissues: 
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Figure 13.  Partial Least Squares – Discriminant Analyses for all detected known 
metabolites in (a). Mouse plasma at 0 and 4 weeks, (b). Mouse Plasma at 4 weeks only, 
(c). Mouse adipose tissue at 4 weeks, (d). Mouse liver tissue at 4 weeks, (e). Mouse 




(c). (d).  
(f). (e). 
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skeletal (p value  0.05), liver (p value  0.01), and adipose (p value  0.01) tissues.  
This trend is not observed in the human plasma samples, where variance among known 
metabolites in undistinguishable between sample types (Zyflamend vs. control) having a 
p value much greater than 0.1. 
 
Unknown Detected Features 
 Using a list of predicted m/z for biologically active molecules known to be in 
Zyflamend, features matching these m/z (within 5 ppm difference in predicted m/z), and 
possibly representing these compounds were found.  Features were found matching 
predicted m/z of biologically active gingerol and Isorosmanol/rosmanol (all forming ions 
as [M-H]-) in plasma, adipose and liver tissues of mice, and were found to have 
significantly higher concentrations in Zyflamend treated mice than the control. Paradol, 
thymol, and carvacrol (all forming ions as [M-H]-) were also found to have matching 
features of significantly higher concentration in Zyflamend treated mice plasma than the 
control.  Carvacrol and thymol specifically, were not observed in plasma samples as 
significantly different in concentration until after 4 weeks of treatment.  Because these 
molecules have not yet been incorporated into the processing method to be matched 
with standards for retention time and observed m/z, it cannot be said with confidence 
that these molecules can be strictly identified, but these matching features are 
observed.  However, knowing that these molecules are components of Zyflamend and 
show significantly higher concentrations in Zyflamend treated samples, this does 
provide reason for method development to further verify, as those bioactive components 
could play major roles in cancer cell growth reduction. 
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To observe overall changes in relative metabolite concentration a partial least 
squares discriminant analysis (PLS-DA) was used to observe these changes amongst 
the unknowns in different mice blood samples.  Through the PLS-DA, it can be 
observed that there are shifts in metabolite concentration after Zyflamend treatment of 4 
weeks and is depicted in Figure 14. Using the PLS-DA we are able to see that these 
samples are indeed significantly different from one another using an F-test giving a p 
value less than 0.05. While the Zyflamend and control samples at 0 weeks seem to 
have no separation among values, after treatment, though there are changes in both 
sample types from their initial metabolite concentration, those populations both shift but 
are still different from one another, they shift their metabolomes, but in different 
directions in variation. 
Only 32 different unknown m/z were found to be statistically significant changes 
in concentration between the Zyflamend treated mice at 0 weeks and the control mice at 
0 weeks while at 4 weeks there were 107 different unknown m/z identified at statistically 
different concentrations between the Zyflamend treated mice and the controls.  A similar 
trend was seen in the human samples, only 4 features found to be different at 0 weeks, 
but 36 different features after 8 weeks of treatment with Zyflamend.  All significant 
unknowns found in these samples are depicted in a heat map (Figure 15) to illustrate 
their significance and corresponding fold change among sample types. Average peak 
intensities for each spectral feature are compared for Zyflamend treated samples to the 
control samples and reported in log2 scale demonstrating fold changes. Features shown 
in red show that concentration of that feature are higher in Zyflamend treated samples 
than control samples and lower in Zyflamend treated samples for features shown in  
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Figure 14.  Partial Least Squares – Discriminant Analysis for unknown spectral features 
observed in mouse plasma at 0 weeks and 4 weeks for both Zyflamend treated and 
control samples. 
 
blue. This in combination with the PLS-DA (Figure 14) applied to the data shows that 
the Zyflamend treatment has caused a shift in the metabolome.  Among those 
unknowns detected in the mice blood plasma samples, 3 unknowns also seen in the 
human samples were found to be statistically significant (p   0.01) and showed similar 
fold changes in peak intensity. 
Further examining the unknowns found in mouse and human plasma, there are 7 
common unknowns that are observed at statistically different (p  0.05) between 
Zyflamend and control samples in the mice at 4 weeks and the humans at 8 weeks.  
These 7 unknowns, though have varying magnitudes of fold changes all change in the 




Figure 15. Heat maps showing fold changes of unknown 
spectral features. (a). Heat map showing concentration ratios 
of Zyflamend treated sample to control samples for all detected 
unknown features with at least one significant fold change in 
human plasma at 0 weeks and 8 weeks, and mouse plasma 
at 0 weeks and 4 weeks. (b). Heat map showing only common 
significant features in both mice and humans (*** p   0.01, ** 





decrease.  This is displayed in a heat map, Figure 15(b), containing only these 7 
common unknowns to show the pattern across sample types.  This shows that a group 
of unknown metabolites are changing in the same way in human and mice. 
 
Conclusion 
 The data shows a shift in metabolome, not only for known metabolites, but even 
more exaggerated in the unknown detected spectral features showing differences 
between Zyflamend treated and control metabolite concentrations. Significant 
differences in metabolite concentrations involved in the TCA cycle and purine 
metabolism across mouse plasma, liver, and adipose tissues. Differences were less 
obvious in human plasma samples, but could be due to more variation in genetics, 
weight, diet and activity levels or the advancement of their cancer in each individual 
case. Even though there are fewer experimental controls among the human samples, 
there are still unknown features that change similarly in mice plasma samples with 
significance indicating that those compounds may be involved in or result from 
metabolic changes responsible for reduction of tumor growth rates.  This encourages 
the mouse model for metabolomics to further study castrate-resistant prostate cancer 
and using Zyflamend as additional treatment.   
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 The relationship between biology and chemistry has been probed both looking 
for responses in changing molecular structure to observe a different biological effect as 
well as a different biological effect observed, and the molecules responsible sought 
after.  Molecular composition of an organism can vastly alter the phenotype. 
 Molecules, when involved in protein transformation, such as the glucocorticoid 
and the glucocorticoid receptor, slight functional group modifications on the molecule 
can have drastically different outcomes with regards to protein function, as described in 
previous work, and what is studied in this work. The synthesis and characterization of 
these 5 new glucocorticoids will further understand this relationship. 
 The entire metabolomes of both malaria resistant and malaria susceptible mice 
were studied to elucidate 8 different compounds shown to be significantly different in 
concentration between populations. Those compounds were further studied using m/z 
and isotope analysis to determine molecular formulae. Allowing for the determination of 
possible biomarkers and aid in the identification of novel biological molecules.  This 
focuses from phenotype down to molecular causation as opposed to before, where the 
molecular structure was studied to observe phenotype. 
 The same untargeted metabolomics technique was applied studying the effects 
of using dietary supplement Zyflamend, and olive oil as the control, showing that there 
were many significant changes in both known and unknown metabolites over plasma, 
adipose, liver, and skeletal muscle tissues involving purine metabolism and the TCA 
cycle. This was particularly enlightening by how the plasma samples were observed as 
changing over time, as well as with treatment with Zyflamend. Overall, these studies 
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showed distinct changes and direct relationships between molecular composition and 
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Unknown Spectral Features found in Malaria Resistant and Susceptible Mice and 
PLS-DA Variates and Loadings 
Malaria 
Table S1.  Spectral Features Detected in Plasma, Cecum, and Small Intestine Tissues 
of Resistant and Susceptible Mice (Log2 Peak Area Ratios, *** p   0.001, ** p  0.05, * 















111.0041(-,-,-) 1.904586 0.826337738 -0.444485066 -1.961885165 
117.0027(-,**,-) 11.07784 0.457804739 -0.676951941 -0.529373097 
118.0059(-,**,-) 11.07733 0.528362085 -0.67282457 -0.527501762 
124.9928(**,-,-) 1.17425 0.586981507 0.222703143 -0.187467316 
126.887(-,**,-) 9.277174 -0.307345025 -1.232793042 -0.282042183 
129.0376(-,-,-) 14.12729 0.125036852 0.079037301 -0.231140303 
129.0376(-,-,-) 13.76722 0.006606287 -0.184313925 0.118136491 
132.9958(-,-,-) 11.65441 0.244786824 -0.29871295 -0.366996934 
133.9989(-,-,-) 11.59331 0.275406652 0.939160178 -0.381016146 
137.0146(-,-,-) 14.44396 -0.942951165 -0.756183026 -0.398937726 
138.9607(-,***,**) 12.10361 -0.029986466 2.58577285 0.97142565 
144.0296(-,-,-) 6.373106 -0.042565423 -0.055162976 1.56425876 
145.0139(-,-,-) 12.00809 0.167853292 0.251614738 0.633552099 
146.0172(-,-,-) 12.00235 0.165642688 0.260151998 0.81916913 
147.0296(-,-,-) 11.68279 -0.148410197 0.105188343 -0.458031781 
149.061(***,***,**) 15.71296 -4.253307076 -7.779644113 -2.214227511 
153.0196(-,-,-) 15.10144 -0.223311668 -0.693019415 0.352592226 
154.023(-,-,-) 15.0892 -0.179668333 -0.719583999 0.239309219 
155.01(-,-,-) 7.825408 0.002697373 -0.181323659 0.978576182 
157.0376(-,-,-) 1.279873 0.323555435 -0.633895928 0.269150872 
160.0625(-,-,-) 7.029578 0.17595059 -1.897276441 -0.448673726 
164.0365(-,-,-) 13.78207 0.274869437 -0.342497986 -0.377796651 
164.0728(-,-,-) 4.356623 -0.006763449 -0.453962065 -0.914657682 
165.0575(**,***,-) 13.12218 2.059878815 1.94780345 -0.454234761 
166.0195(-,***,***) 7.179941 0.482024404 2.471146955 1.493588895 
166.9976(-,-,-) 11.99546 -0.104096032 -0.316379598 0.583771496 
172.9941(-,-,-) 13.90116 -0.332042486 -0.988564856 -0.069666616 
173.0117(-,-,-) 12.90411 -0.161246676 0.158746975 0.39221844 
173.9972(-,-,-) 13.90388 -0.284420122 -1.021765221 -0.134152756 
174.0434(-,-,-) 11.77508 0.123928886 0.46211606 0.332915191 
174.9897(-,-,-) 13.9063 -0.242502217 -0.964581331 -0.119521532 
175.0273(-,-,-) 12.74443 -0.48350372 -1.616583721 0.03237319 
175.0274(-,-,-) 5.54275 5.751692138 -3.011137875 -0.069007331 
180.0695(-,-,-) 2.653936 -0.063320119 -0.380222858 -0.962594529 
181.0534(-,-,-) 10.98547 -0.05741749 2.04165949 1.805053111 
188.0048(-,-,-) 12.48772 -0.313549335 -0.464686662 0.104578365 
188.0126(-,***,-) 15.24653 -0.292562332 -3.048821027 0.47994983 
188.059(-,-,-) 11.86648 0.187856736 -0.160597903 -0.43308497 
188.0743(-,*,-) 15.39997 -0.238030376 -0.694923237 -0.074077239 
188.9885(-,-,-) 13.54714 -0.417490808 -1.341426722 0.232334512 
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189.9922(-,-,-) 13.55239 -0.458934931 -1.549543154 0.263476744 
190.0564(-,-,-) 11.6512 0.315717794 -0.597059916 -0.081669332 
192.0692(-,-,-) 13.70416 0.406093534 0.228463355 0.159221685 
194.9297(-,-,-) 12.15323 -0.415638077 4.503028042 -0.337273567 
196.9254(-,-,-) 12.15484 -0.427700647 5.045871601 -0.371886737 
199.9709(-,-,-) 6.370483 0.108802004 0.384972502 -0.507095395 
203.0849(-,-,-) 7.344273 -0.115917358 -0.51714128 -0.415380661 
204.0683(***,-,**) 15.24915 -4.445347243 1.049206199 -4.586847959 
204.0688(-,-,*) 14.20704 0.82487903 2.502412077 1.981881355 
204.9829(-,-,-) 13.39977 2.767144217 3.503798401 2.851596489 
212.0043(-,-,-) 14.20936 -0.268248819 0.324672698 -0.130175474 
213.0057(-,-,-) 14.22312 -0.226902565 0.288655844 -0.271891325 
213.0062(-,-,-) 14.20975 -0.193170168 0.059305628 -0.175996189 
214.0003(-,-,-) 14.21942 -0.202220189 0.544985848 -0.206597452 
218.1048(**,-,-) 9.916399 0.557726586 -0.051046925 -0.806467176 
219.1079(**,-,-) 9.963799 0.62380655 -0.036070521 -0.839587944 
223.0214(-,-,-) 0.9696301 -0.019471284 -0.007544324 0.134321536 
224.025(**,***,***) 11.83593 0.518647282 3.228606617 1.881749866 
229.1201(-,-,**) 9.446461 0.516347454 0.90763943 0.993876935 
232.001(-,-,-) 13.6007 0.995845666 2.265128353 1.520160158 
232.0011(-,-,-) 13.6007 0.993036581 2.239264764 1.521904864 
232.9935(-,-,-) 13.60263 0.963985506 2.293824075 1.638221956 
235.0831(-,-,-) 9.209479 0.949258193 -0.073132091 0.556190342 
236.0243(-,-,-) 11.44164 0.28139295 0.182570526 -0.361912201 
236.0866(-,-,-) 9.195724 0.946938273 -0.157355719 0.452642307 
239.9984(**,-,**) 13.92008 3.279804078 6.699752888 2.71475124 
242.0141(***,*,**) 14.1175 4.410499168 3.387067891 3.921286718 
242.0504(-,-,***) 13.71584 0.887198088 1.929449731 1.928766246 
242.9975(-,-,-) 14.40491 0.886587295 1.635905891 0.813264187 
242.9976(*,-,-) 13.92985 0.621227631 0.566652004 0.967637021 
243.0626(-,**,-) 1.794611 0.311552357 -0.926864962 -0.567459011 
243.0628(**,-,-) 2.811702 0.591888009 -0.182305154 -0.016938423 
245.013(***,-,-) 14.28598 2.016950313 1.32951463 2.031505486 
246.0165(***,-,-) 14.28487 2.180938361 1.405295064 2.027893891 
247.0088(**,-,-) 14.28699 2.272759724 1.503019962 2.054850737 
247.0167(***,-,-) 14.27737 2.355519083 1.434889001 2.091396571 
252.0102(-,-,-) 15.21041 0.349617373 -0.304966007 -0.043007055 
253.0182(-,-,-) 15.11305 0.783762586 -0.148630674 -0.006721091 
254.0802(*,-,-) 9.974265 0.640529851 -0.144436503 -0.979445325 
254.982(**,-,-) 10.59487 0.548431103 -0.164209918 0.598381915 
255.9854(**,-,-) 10.59877 0.664584537 -0.149771995 0.598053705 
256.9778(**,-,-) 10.59972 0.675255701 -0.181090999 0.615549138 
256.9862(**,-,-) 10.5977 0.637766448 -0.028643476 0.604751566 
258.9908(-,-,-) 14.12834 -0.523860817 1.26288673 0.118782507 
259.1296(-,**,-) 11.4689 -0.145808048 -0.814841048 -1.410830548 
261.0072(-,***,***) 13.38481 -0.170195919 6.63685076 1.724264653 
275.0227(-,-,-) 13.85964 -0.538138991 1.551298914 0.439664816 
275.0228(-,-,-) 13.85936 -0.547220571 1.530130662 0.440390776 
275.0885(-,-,-) 11.11561 -0.317244694 -0.281009577 -0.918962194 
277.0855(-,-,-) 9.463263 -0.667276532 -0.496365212 -1.58676987 
279.0987(-,-,-) 11.94635 -2.809848543 0.026378301 -0.47051522 
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283.0823(-,*,-) 14.33755 -0.72125513 -2.112044766 1.153967627 
283.0823(-,*,-) 14.34513 -0.719167298 -2.23186137 1.155015822 
283.0841(-,-,-) 14.20187 -5.050002827 0.070364229 1.222047919 
284.0862(-,*,-) 14.3511 -0.735785619 -2.642008894 1.276746965 
286.0024(***,-,-) 13.74559 -2.393733896 0.247734574 -1.032307249 
293.1761(-,-,-) 17.44849 -0.074193101 0.088899997 0.008089683 
294.1193(-,**,-) 1.264356 -0.190195419 -0.93144421 -1.014449071 
300.0753(*,**,-) 1.244906 0.877456117 -1.746160685 -0.662851028 
301.0591(-,-,-) 7.342644 -0.036725698 -0.475544343 -0.525635313 
301.2161(-,-,-) 18.45179 1.943050059 0.450491753 -0.05880335 
307.9482(***,-,-) 14.28363 2.75106314 1.640515408 2.084804038 
310.1253(-,***,-) 1.250716 0.29951377 -2.101627823 -0.212311802 
316.0797(*,-,-) 9.957761 0.665453977 0.217509042 -1.057549085 
316.1046(-,-,-) 2.652814 -0.141459452 -0.41587155 -1.807435817 
321.0435(-,-,-) 16.24352 -0.342444872 -0.35935621 -0.476053109 
322.0468(-,-,-) 16.24688 -0.319169182 -0.213851625 -0.417883171 
325.1248(-,**,-) 1.167299 -0.020586416 -1.794082443 -0.929015327 
335.0492(-,*,-) 5.772844 0.38455079 -1.458664156 -1.620519177 
336.0727(**,-,*) 12.59202 9.557649071 1.326007587 5.159209562 
338.0879(***,-,*) 13.04792 5.791877525 1.860480525 4.822327998 
339.9772(-,-,-) 16.94036 -0.132795039 0.138906989 0.430239143 
348.1914(***,-,-) 13.2253 -1.14803599 0.70770919 -2.172726954 
359.1183(-,-,-) 1.192552 0.005430759 -1.645815871 -0.805499961 
361.1402(-,-,-) 2.641605 0.335700212 -0.533482624 -1.170882088 
377.1822(*,-,*) 10.75672 -1.563484546 -0.411093338 -1.462809751 
378.1851(*,-,-) 10.83899 -1.60335374 0.126471138 -5.892867177 
386.0341(-,-,-) 11.96699 -0.139095371 1.136877047 -0.80712462 
387.0392(-,-,*) 11.94579 -0.186942937 2.477284586 -0.920210328 
389.2444(**,-,-) 18.60937 6.494216856 4.262144747 -0.610083815 
389.2461(**,-,-) 18.59786 6.258223129 4.413028009 -0.608953017 
407.1718(-,-,-) 7.352286 -0.09622374 -0.865842523 -0.842203528 
411.2753(-,-,-) 18.38797 5.438744646 -2.261548238 -2.466001834 
413.2913(**,-,-) 18.64072 5.47689756 5.319981372 -0.929919426 
414.2959(**,-,-) 18.64086 5.65088525 4.937919612 -0.949349488 
414.2978(**,-,-) 18.60483 5.526703143 4.308344172 -0.85543421 
424.0373(-,-,-) 10.35866 -0.241126611 -2.29594102 1.275229925 
437.2133(**,-,-) 9.963844 1.633504864 0.472281017 -2.095045483 
437.2897(*,-,-) 18.43929 6.756900891 4.108827001 -1.924345373 
438.217(**,-,-) 9.964466 1.536208425 0.476300753 -2.142419986 
495.119(**,-,-) 14.67132 -1.290206318 -2.043436143 -1.360791428 
514.2833(-,-,-) 17.20452 1.625761957 2.972319512 0.197718692 
514.2833(-,-,-) 17.61292 1.389677091 1.853113245 0.111452948 
515.2853(-,-,-) 17.60541 1.384619446 1.819880006 0.106817526 
519.209(**,-,**) 14.5765 -1.245281792 -0.179788991 -1.861646803 
519.709(**,-,*) 14.51333 -1.254616508 1.447820089 -2.595392905 
520.7035(**,-,-) 15.4914 -1.991888404 0.178436774 -0.010377425 
521.2057(**,-,-) 15.51379 -2.020092412 -0.46320891 0.07518054 
563.2819(***,NA,*) 12.42059 -0.614481816 0 -1.985522485 
580.2549(-,*,-) 12.48402 -0.487310983 1.474879165 -5.594173029 
581.2585(-,**,-) 12.50202 -0.495793781 -2.951170118 -2.057945436 
594.738(**,-,-) 16.5613 -2.172699541 -11.16083736 -10.93930697 
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606.0739(-,-,-) 11.88694 1.024303065 -0.42171316 0.703028281 
611.1432(-,**,-) 11.37524 -0.135516013 -2.297393744 -0.060821366 
612.147(-,**,-) 11.38115 -0.108921521 -2.29615104 -0.077479128 
619.2877(-,-,-) 18.35714 0.002914607 -0.53049837 -1.292789236 
633.0346(-,-,-) 0.9886361 -0.119774789 0.454959296 0.110535965 
650.7794(*,-,**) 15.46245 -2.108025579 -0.149588676 -13.90790308 
651.2852(*,-,-) 15.48932 -2.09154211 0.10482271 0.589627828 
674.3713(-,NA,NA) 12.87967 -1.751109641 0 0 
675.3741(-,NA,-) 12.88513 -1.767539297 0 -10.75028879 
716.863(**,NA,-) 16.95988 -1.558856112 0 -13.31141791 
726.3444(***,*,-) 13.68137 -0.833479512 12.68168764 -0.246736676 
784.1486(-,-,-) 14.6774 -1.093684317 -0.080477136 -0.148507939 
785.1524(-,-,-) 14.67034 -1.082437362 -0.092596689 -0.271227672 
790.322(-,-,-) 16.65425 -0.852781887 -14.68129433 -2.926310406 
790.8239(-,-,-) 16.62698 -0.87409365 -11.63913624 12.13008413 
791.3301(-,***,-) 16.65097 -0.910096436 1.323016619 -0.19518596 
809.3873(*,-,-) 16.76484 -1.3220692 -0.250517359 0.240111346 
852.8983(-,-,-) 16.91214 -0.945096182 -15.83793465 -1.958261798 
917.481(-,NA,NA) 17.98472 -1.235412341 0 0 
111.0041(-,-,-) 1.904586 0.826337738 -0.444485066 -1.961885165 
     
     
     
 
Table S2.  Malaria: PLS-DA Unknown Variates Plasma for Resistant and Susceptible 
Mice 
Mouse X1 X2 Y1 Y2 
JAX 1 6.3272 3.6284 1.3416 0.0737 
JAX 2 4.1054 6.2131 1.3416 0.5189 
JAX 3 7.3316 -2.9233 1.3416 -0.1276 
JAX 4 5.3223 3.4710 1.3416 0.2751 
JAX 5 7.9131 -5.2285 1.3416 -0.2441 
NCI 1 -4.1933 -5.6704 -1.3416 -0.5013 
NCI 2 -7.4411 1.1518 -1.3416 0.1495 
NCI 3 -9.2502 4.1112 -1.3416 0.5120 
NCI 4 -3.6749 -4.3121 -1.3416 -0.6052 







Table S3.  Malaria: PLS-DA Unknowns Cecum Variates 
Mouse X1 X2 Y1 Y2 
JAX 1 7.45292 -2.13615 1.32288 -0.34058 
JAX 2 5.29527 -0.24144 1.32288 0.14100 
JAX 3 3.73637 9.70951 1.32288 0.48894 
JAX 4 5.71796 -4.00599 1.32288 0.04665 
NCI 1 -6.60409 -0.77901 -1.32288 0.15113 
NCI 2 -6.36448 -0.27118 -1.32288 0.09765 
NCI 3 -6.37671 2.71239 -1.32288 0.10038 
NCI 4 -2.85724 -4.98814 -1.32288 -0.68515 
 
Table S4.  Malaria: PLS-DA Unknowns Small Intestine Variates 
 X.comp.1 X.comp.2 Y.comp.1 Y.comp.2 
JAX 1 6.7315 -3.3474 1.3416 -0.3374 
JAX 2 6.0781 2.2287 1.3416 -0.1745 
JAX 3 4.4572 0.5783 1.3416 0.2298 
JAX 4 3.6890 5.0353 1.3416 0.4215 
JAX 5 3.1076 1.7819 1.3416 0.5665 
NCI 1 -7.9384 10.3085 -1.3416 0.6385 
NCI 2 -2.1199 -5.0282 -1.3416 -0.8128 
NCI 3 -4.1603 -5.5389 -1.3416 -0.3039 
NCI 4 -5.2298 -4.3139 -1.3416 -0.0371 
NCI 5 -4.6150 -1.7044 -1.3416 -0.1905 
Table S5.  Malaria: PLS-DA Unknowns  Plasma Loadings 
m/z comp 1 comp 2 m/z comp 1 comp 2 m/z comp 1 comp 2 
242.0141 0.147 0.069 232.9935 0.055 -0.030 188.9885 -0.030 -0.099 
338.0879 0.144 0.059 160.0625 0.052 -0.070 174.9897 -0.030 -0.022 
336.0727 0.140 0.029 301.2161 0.051 0.027 203.0849 -0.033 -0.025 
239.9984 0.136 0.031 236.0243 0.048 -0.119 153.0196 -0.033 -0.004 
307.9482 0.133 0.060 242.0504 0.045 -0.044 175.0273 -0.033 0.040 
247.0088 0.132 0.049 190.0564 0.044 -0.069 316.1046 -0.036 -0.173 
246.0165 0.132 0.049 361.1402 0.040 0.004 633.0346 -0.037 -0.015 
245.013 0.132 0.050 188.059 0.034 -0.143 173.9972 -0.038 -0.038 
247.0167 0.131 0.065 252.0102 0.033 0.033 322.0468 -0.046 -0.006 
389.2444 0.127 0.000 132.9958 0.030 -0.157 258.9908 -0.046 -0.010 
389.2461 0.126 -0.004 133.9989 0.027 -0.158 172.9941 -0.047 -0.039 
413.2913 0.121 -0.031 174.0434 0.024 -0.198 275.0227 -0.050 -0.027 
414.2978 0.121 -0.024 129.0376 0.023 -0.075 275.0228 -0.051 -0.027 
165.0575 0.120 0.027 145.0139 0.022 -0.099 188.0126 -0.052 -0.169 
414.2959 0.120 -0.024 146.0172 0.018 -0.095 321.0435 -0.054 -0.013 
218.1048 0.114 -0.053 192.0692 0.015 -0.058 852.8983 -0.057 -0.087 
219.1079 0.112 -0.061 199.9709 0.013 -0.199 275.0885 -0.057 -0.031 
437.2133 0.109 -0.079 619.2877 0.007 0.152 126.887 -0.060 -0.030 
437.2897 0.108 -0.027 359.1183 -0.001 -0.014 137.0146 -0.066 0.071 
175.0274 0.106 0.042 144.0296 -0.001 -0.029 790.322 -0.067 0.093 
438.217 0.105 -0.085 155.01 -0.002 0.001 277.0855 -0.067 0.040 
255.9854 0.105 -0.043 164.0728 -0.005 -0.014 790.8239 -0.068 0.091 
124.9928 0.104 -0.045 325.1248 -0.006 0.063 791.3301 -0.068 0.091 
224.025 0.104 0.008 164.0365 -0.006 -0.109 194.9297 -0.071 0.007 
256.9778 0.102 -0.037 138.9607 -0.006 -0.020 196.9254 -0.073 0.008 
256.9862 0.101 -0.053 129.0376 -0.007 -0.067 283.0823 -0.073 -0.147 
254.982 0.100 -0.053 386.0341 -0.009 -0.177 283.0823 -0.073 -0.147 
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Table S5. Continued 
m/z comp 1 comp 2 m/z comp 1 comp 2 m/z comp 1 comp 2 
243.0628 0.099 -0.118 223.0214 -0.009 0.040 284.0862 -0.074 -0.147 
514.2833 0.098 0.065 612.147 -0.011 -0.166 785.1524 -0.081 0.068 
204.9829 0.095 0.002 387.0392 -0.011 -0.175 784.1486 -0.084 0.062 
316.0797 0.092 -0.109 407.1718 -0.013 0.003 917.481 -0.086 0.043 
300.0753 0.091 -0.086 301.0591 -0.014 -0.030 675.3741 -0.088 -0.089 
204.0688 0.089 -0.021 611.1432 -0.015 -0.166 674.3713 -0.089 -0.086 
254.0802 0.088 -0.103 181.0534 -0.015 -0.113 809.3873 -0.094 0.052 
515.2853 0.088 0.081 147.0296 -0.018 -0.164 495.119 -0.099 -0.045 
514.2833 0.087 0.081 293.1761 -0.018 0.128 378.1851 -0.102 0.037 
242.9976 0.085 -0.032 424.0373 -0.018 0.083 377.1822 -0.103 0.038 
229.1201 0.085 -0.063 261.0072 -0.019 0.016 279.0987 -0.105 0.040 
243.0626 0.084 -0.024 213.0062 -0.021 -0.007 650.7794 -0.109 0.042 
606.0739 0.082 -0.007 214.0003 -0.022 -0.011 519.709 -0.110 0.012 
411.2753 0.081 0.063 180.0695 -0.022 -0.042 651.2852 -0.110 0.039 
235.0831 0.077 -0.015 213.0057 -0.023 0.011 519.209 -0.110 0.014 
166.0195 0.076 -0.073 154.023 -0.023 0.002 716.863 -0.113 0.008 
236.0866 0.076 -0.015 188.0048 -0.023 -0.111 594.738 -0.113 0.040 
157.0376 0.071 -0.042 581.2585 -0.024 -0.095 283.0841 -0.120 -0.160 
242.9975 0.069 0.012 339.9772 -0.025 -0.017 520.7035 -0.122 0.016 
118.0059 0.064 -0.126 580.2549 -0.026 -0.095 521.2057 -0.122 0.010 
111.0041 0.064 -0.091 188.0743 -0.028 0.088 726.3444 -0.129 -0.093 
310.1253 0.063 -0.101 166.9976 -0.028 0.035 563.2819 -0.130 -0.093 
253.0182 0.061 0.029 212.0043 -0.028 -0.011 286.0024 -0.132 -0.093 
335.0492 0.061 -0.164 189.9922 -0.029 -0.107 348.1914 -0.137 -0.021 
232.001 0.059 -0.044 173.0117 -0.030 -0.007 204.0683 -0.144 -0.092 
232.0011 0.059 -0.044 259.1296 -0.030 -0.046 149.061 -0.149 -0.080 
117.0027 0.059 -0.126 294.1193 -0.030 0.000 188.9885 -0.030 -0.099 
242.0141 0.147 0.069 232.9935 0.055 -0.030 174.9897 -0.030 -0.022 
338.0879 0.144 0.059 160.0625 0.052 -0.070 203.0849 -0.033 -0.025 
336.0727 0.140 0.029 301.2161 0.051 0.027 153.0196 -0.033 -0.004 
239.9984 0.136 0.031 236.0243 0.048 -0.119 175.0273 -0.033 0.040 
307.9482 0.133 0.060 242.0504 0.045 -0.044 316.1046 -0.036 -0.173 
247.0088 0.132 0.049 190.0564 0.044 -0.069 633.0346 -0.037 -0.015 
246.0165 0.132 0.049 361.1402 0.040 0.004 173.9972 -0.038 -0.038 
245.013 0.132 0.050 188.059 0.034 -0.143 322.0468 -0.046 -0.006 
247.0167 0.131 0.065 252.0102 0.033 0.033 258.9908 -0.046 -0.010 
389.2444 0.127 0.000 132.9958 0.030 -0.157 172.9941 -0.047 -0.039 
389.2461 0.126 -0.004 133.9989 0.027 -0.158 275.0227 -0.050 -0.027 
413.2913 0.121 -0.031 174.0434 0.024 -0.198 275.0228 -0.051 -0.027 
414.2978 0.121 -0.024 129.0376 0.023 -0.075 188.0126 -0.052 -0.169 
165.0575 0.120 0.027 145.0139 0.022 -0.099 321.0435 -0.054 -0.013 
414.2959 0.120 -0.024 146.0172 0.018 -0.095 852.8983 -0.057 -0.087 
218.1048 0.114 -0.053 192.0692 0.015 -0.058 275.0885 -0.057 -0.031 
219.1079 0.112 -0.061 199.9709 0.013 -0.199 126.887 -0.060 -0.030 
437.2133 0.109 -0.079 619.2877 0.007 0.152 137.0146 -0.066 0.071 
437.2897 0.108 -0.027 359.1183 -0.001 -0.014 790.322 -0.067 0.093 
175.0274 0.106 0.042 144.0296 -0.001 -0.029 277.0855 -0.067 0.040 
438.217 0.105 -0.085 155.01 -0.002 0.001 790.8239 -0.068 0.091 
255.9854 0.105 -0.043 164.0728 -0.005 -0.014 791.3301 -0.068 0.091 
124.9928 0.104 -0.045 325.1248 -0.006 0.063 194.9297 -0.071 0.007 
224.025 0.104 0.008 164.0365 -0.006 -0.109 196.9254 -0.073 0.008 
256.9778 0.102 -0.037 138.9607 -0.006 -0.020 283.0823 -0.073 -0.147 
256.9862 0.101 -0.053 129.0376 -0.007 -0.067 283.0823 -0.073 -0.147 
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Table S5. Continued 
m/z comp 1 comp 2 m/z comp 1 comp 2 m/z comp 1 comp 2 
254.982 0.100 -0.053 386.0341 -0.009 -0.177 284.0862 -0.074 -0.147 
243.0628 0.099 -0.118 223.0214 -0.009 0.040 785.1524 -0.081 0.068 
514.2833 0.098 0.065 612.147 -0.011 -0.166 784.1486 -0.084 0.062 
204.9829 0.095 0.002 387.0392 -0.011 -0.175 917.481 -0.086 0.043 
316.0797 0.092 -0.109 407.1718 -0.013 0.003 675.3741 -0.088 -0.089 
300.0753 0.091 -0.086 301.0591 -0.014 -0.030 674.3713 -0.089 -0.086 
204.0688 0.089 -0.021 611.1432 -0.015 -0.166 809.3873 -0.094 0.052 
254.0802 0.088 -0.103 181.0534 -0.015 -0.113 495.119 -0.099 -0.045 
515.2853 0.088 0.081 147.0296 -0.018 -0.164 378.1851 -0.102 0.037 
514.2833 0.087 0.081 293.1761 -0.018 0.128 377.1822 -0.103 0.038 
242.9976 0.085 -0.032 424.0373 -0.018 0.083 279.0987 -0.105 0.040 
229.1201 0.085 -0.063 261.0072 -0.019 0.016 650.7794 -0.109 0.042 
243.0626 0.084 -0.024 213.0062 -0.021 -0.007 519.709 -0.110 0.012 
606.0739 0.082 -0.007 214.0003 -0.022 -0.011 651.2852 -0.110 0.039 
411.2753 0.081 0.063 180.0695 -0.022 -0.042 519.209 -0.110 0.014 
235.0831 0.077 -0.015 213.0057 -0.023 0.011 716.863 -0.113 0.008 
166.0195 0.076 -0.073 154.023 -0.023 0.002 594.738 -0.113 0.040 
236.0866 0.076 -0.015 188.0048 -0.023 -0.111 283.0841 -0.120 -0.160 
157.0376 0.071 -0.042 581.2585 -0.024 -0.095 520.7035 -0.122 0.016 
242.9975 0.069 0.012 339.9772 -0.025 -0.017 521.2057 -0.122 0.010 
118.0059 0.064 -0.126 580.2549 -0.026 -0.095 726.3444 -0.129 -0.093 
111.0041 0.064 -0.091 188.0743 -0.028 0.088 563.2819 -0.130 -0.093 
310.1253 0.063 -0.101 166.9976 -0.028 0.035 286.0024 -0.132 -0.093 
253.0182 0.061 0.029 212.0043 -0.028 -0.011 348.1914 -0.137 -0.021 
335.0492 0.061 -0.164 189.9922 -0.029 -0.107 204.0683 -0.144 -0.092 
232.001 0.059 -0.044 173.0117 -0.030 -0.007 149.061 -0.149 -0.080 
232.0011 0.059 -0.044 259.1296 -0.030 -0.046    




Table S6.  Malaria: PLS-DA Unknowns Cecum Loadings 
m/z comp 1 comp 2 m/z comp 1 comp 2 m/z comp 1 comp 2 
261.0072 0.167 0.053 133.9989 0.052 0.123 132.9958 -0.047 0.059 
224.025 0.160 0.040 633.0346 0.048 -0.058 254.0802 -0.049 -0.033 
165.0575 0.158 0.077 124.9928 0.044 0.103 321.0435 -0.050 0.013 
138.9607 0.157 0.034 213.0062 0.040 0.116 153.0196 -0.052 0.025 
166.0195 0.157 0.029 173.0117 0.038 0.072 164.0728 -0.053 0.162 
791.3301 0.149 0.028 174.0434 0.038 0.003 316.1046 -0.054 0.146 
242.0141 0.137 0.068 283.0841 0.036 0.108 252.0102 -0.058 0.061 
194.9297 0.129 0.032 784.1486 0.035 0.001 275.0885 -0.058 0.041 
196.9254 0.129 0.031 438.217 0.034 0.066 164.0365 -0.060 0.128 
514.2833 0.119 -0.045 785.1524 0.034 0.001 111.0041 -0.063 0.076 
242.0504 0.119 0.016 199.9709 0.032 0.112 359.1183 -0.066 0.023 
239.9984 0.118 0.047 214.0003 0.032 0.094 157.0376 -0.067 0.066 
204.0688 0.116 0.129 437.2133 0.031 0.083 203.0849 -0.071 0.115 
338.0879 0.115 0.144 223.0214 0.029 0.040 361.1402 -0.073 0.134 
181.0534 0.114 -0.017 144.0296 0.023 0.119 377.1822 -0.074 -0.015 
386.0341 0.110 0.094 212.0043 0.023 0.095 189.9922 -0.075 0.055 
336.0727 0.103 0.132 286.0024 0.022 0.055 175.0274 -0.075 0.048 
387.0392 0.098 0.114 147.0296 0.022 -0.084 301.0591 -0.075 0.098 
389.2461 0.097 -0.107 301.2161 0.019 0.141 180.0695 -0.077 0.142 
389.2444 0.095 -0.108 192.0692 0.018 0.148 277.0855 -0.077 0.095 
413.2913 0.094 -0.109 236.0243 0.017 -0.002 188.9885 -0.081 0.038 
437.2897 0.093 -0.104 145.0139 0.016 -0.026 190.0564 -0.091 0.092 
414.2978 0.091 -0.099 146.0172 0.014 -0.033 160.0625 -0.092 -0.206 
242.9975 0.091 -0.011 279.0987 0.005 -0.005 175.0273 -0.094 0.019 
242.9976 0.090 -0.009 253.0182 0.000 0.014 188.0743 -0.096 0.020 
307.9482 0.089 0.063 129.0376.1 -0.001 0.056 174.9897 -0.097 0.083 
247.0088 0.088 0.074 293.1761 -0.005 -0.138 173.9972 -0.097 0.097 
245.013 0.088 0.072 411.2753 -0.010 -0.117 335.0492 -0.098 0.042 
247.0167 0.088 0.073 256.9862 -0.012 0.075 172.9941 -0.099 0.073 
246.0165 0.088 0.068 188.0048 -0.013 0.064 495.119 -0.100 0.051 
414.2959 0.087 -0.107 219.1079 -0.019 0.059 283.0823 -0.112 0.108 
204.9829 0.087 0.009 255.9854 -0.019 0.079 283.0823.1 -0.113 0.105 
515.2853 0.083 -0.072 256.9778 -0.021 0.069 284.0862 -0.117 0.108 
514.2833 0.083 -0.073 606.0739 -0.022 -0.031 243.0626 -0.119 0.092 
204.0683 0.080 0.141 254.982 -0.023 0.068 259.1296 -0.119 0.047 
275.0228 0.077 -0.015 218.1048 -0.025 0.052 325.1248 -0.122 -0.012 
275.0227 0.076 -0.015 235.0831 -0.027 0.188 612.147 -0.129 0.026 
258.9908 0.073 -0.023 236.0866 -0.030 0.214 611.1432 -0.130 0.022 
339.9772 0.072 -0.067 129.0376 -0.031 0.010 300.0753 -0.132 0.012 
232.001 0.072 0.100 322.0468 -0.035 0.043 118.0059 -0.136 -0.069 
232.0011 0.072 0.099 154.023 -0.038 0.028 117.0027 -0.137 -0.067 
232.9935 0.072 0.099 188.059 -0.039 -0.091 188.0126 -0.140 -0.007 
229.1201 0.070 0.153 243.0628 -0.041 0.124 294.1193 -0.140 -0.024 
316.0797 0.068 0.025 137.0146 -0.043 0.026 126.887 -0.149 -0.095 
651.2852 0.056 -0.211 155.01 -0.044 -0.049 310.1253 -0.149 -0.003 






Table S7.  Malaria: PLS-DA Unknowns Small Intestine Loadings 
m/z comp 1 comp 2 m/z comp 1 comp 2 m/z comp 1 comp 2 
242.01 0.180 0.060 223.02 0.030 0.064 196.93 -0.058 0.088 
224.03 0.180 0.107 154.02 0.029 -0.137 389.25 -0.059 -0.066 
242.05 0.175 0.102 424.04 0.026 -0.066 389.24 -0.059 -0.066 
166.02 0.174 0.161 633.03 0.024 0.050 188.06 -0.059 0.127 
240 0.169 0.076 129.04 0.023 0.149 325.12 -0.061 -0.079 
261.01 0.162 0.125 339.98 0.020 0.069 300.08 -0.061 -0.044 
338.09 0.158 0.007 192.07 0.017 0.074 414.3 -0.065 -0.062 
336.07 0.156 -0.002 174.04 0.016 0.135 199.97 -0.068 0.050 
229.12 0.150 0.172 188.99 0.016 -0.047 294.12 -0.069 -0.072 
138.96 0.146 0.129 188.01 0.015 -0.097 414.3 -0.071 -0.065 
204.98 0.128 -0.026 189.99 0.012 -0.051 413.29 -0.071 -0.066 
247.02 0.117 0.001 293.18 0.012 0.189 164.04 -0.071 0.031 
247.01 0.117 0.004 243.06 0.012 0.165 301.06 -0.072 0.092 
307.95 0.117 0.004 258.99 0.007 -0.007 275.09 -0.072 0.054 
181.05 0.117 0.102 188 0.006 -0.025 165.06 -0.074 0.048 
245.01 0.116 0.001 611.14 0.004 0.068 279.1 -0.075 -0.022 
246.02 0.116 0.002 612.15 0.004 0.062 259.13 -0.076 0.107 
204.07 0.115 0.111 175.03 0.002 0.061 277.09 -0.079 0.109 
243.1 0.105 0.033 253.02 0.002 -0.033 243.06 -0.080 0.092 
232.99 0.094 -0.035 175.03 -0.005 0.080 407.17 -0.082 0.073 
232.1 0.091 -0.033 301.22 -0.008 0.014 619.29 -0.087 0.078 
232 0.091 -0.033 252.01 -0.009 -0.122 254.08 -0.087 0.111 
606.07 0.086 0.079 212 -0.010 -0.065 437.29 -0.088 -0.039 
283.08 0.086 0.092 188.07 -0.013 0.055 495.12 -0.088 0.110 
167 0.082 0.157 190.06 -0.013 0.166 316.08 -0.088 0.088 
243 0.081 0.011 213.01 -0.015 -0.073 117 -0.089 0.128 
144.03 0.077 -0.030 784.15 -0.017 0.112 118.01 -0.089 0.127 
145.01 0.067 0.107 214 -0.018 -0.072 218.1 -0.090 0.119 
146.02 0.065 0.103 172.99 -0.019 -0.119 219.11 -0.092 0.118 
235.08 0.064 0.069 213.01 -0.023 -0.084 316.1 -0.100 0.102 
155.01 0.062 -0.020 174.99 -0.025 -0.130 180.07 -0.100 0.088 
256.98 0.061 0.022 174 -0.025 -0.134 411.28 -0.102 0.012 
254.98 0.058 0.019 310.13 -0.027 -0.042 286 -0.106 -0.004 
255.99 0.057 0.021 124.99 -0.029 0.072 386.03 -0.107 0.046 
236.09 0.056 0.067 785.15 -0.029 0.108 111 -0.111 0.091 
256.99 0.055 0.016 236.02 -0.030 0.017 164.07 -0.113 0.084 
283.08.2 0.054 -0.021 322.05 -0.034 0.110 387.04 -0.113 0.040 
283.08 0.054 -0.021 359.12 -0.037 -0.123 361.14 -0.115 0.076 
284.09 0.052 -0.030 133 -0.037 0.060 335.05 -0.121 0.090 
153.02 0.049 -0.115 134 -0.037 0.060 438.22 -0.123 0.088 
514.28 0.048 0.109 129.04 -0.040 0.123 437.21 -0.124 0.087 
275.02 0.046 0.003 126.89 -0.041 -0.032 852.9 -0.127 0.000 
275.02 0.046 0.003 321.04 -0.041 0.107 348.19 -0.133 0.094 
651.29 0.046 -0.028 147.03 -0.051 0.108 377.18 -0.141 0.052 
173.01 0.042 0.001 137.01 -0.052 -0.100 519.21 -0.153 0.047 
157.04 0.038 -0.001 160.06 -0.054 0.089 149.06 -0.158 -0.035 
514.28 0.031 0.103 194.93 -0.054 0.090 204.07 -0.176 -0.026 
515.29 0.030 0.101 203.08 -0.058 0.092 196.93 -0.058 0.088 
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 150.068276 C9H10O2 9.76 0 1.309 
   C2H10N6S   3.259 
 [M-H+H2O]
-





 133.041776 C2H7N5S   3.3 
 [M-H+ACN]
-










 131.095376 C6H13NO2 9.9 .02 5 
204.0683 [M-H]
-
 205.075576 C4H11N7OS 9.77 .13 4.8 
 [M-H+H2O]
-
 187.064976 C4H9N7S   5 
224.025 [M-H]
-
 225.032276 C7H7N5O2S 5.73 4.55 1.026 
   C6H13NO4P2   1.311 
   C15H3N3   1.871 
   C7H15NOS3   3.11 
   C7H9N5P2   4.632 
 [M-H+H2O]
-
 207.021676 C7H5N5OS   0.944 
   C6H11NO3P2   1.255 





 208.005776 C7H4N4O2S   1.346 
   C6H10O4P2   1.655 
   C15N2   1.788 
   H4N10S2   1.95 
   C7H12OS3   3.6 
   C7H6N4P2   4.775 
 [M-H+ACN]
-
 184.005776 C5H4N4O2S   1.521 
   C4H10O4P2   1.87 
   C13N2   2.022 
   C5H12OS3   4.07 





 165.0111 C5H3N5S   1.116 





 203.050352 CH9N5O7   0.76 










 190.062876 C11H10O3   0.622 
   C4H10N6OS   4.228 
   C5H11N4O2P   4.808 
239.9984 [M-H]
-
 241.005676 C9H9NO3P2   0.374 
   C10H3N5OS   0.641 
   C10H11NS3   1.305 
   C2H7N7O3S2   2.064 
   C2H9N7OP2S   3.218 
   C4H4N9PS   3.642 
   C3H10N5O2P3   3.908 
   C9H7NO5S   4.908 
 [M-H+H2O]
-
 222.995076 C9H7NO2P2   0.563 
   C10HN5S   0.851 
   C2H5N7O2S2   2.073 
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 222.995076 C2H7N7P2S   3.637 
   C3H8N5OP3   4.065 





 223.979176 C9H6O3P2   0.183 
   C10N4OS   0.47 
   C10H8S3   1.624 
   C2H4N6O3S2   2.44 
   C2H6N6OP2S   3.244 
   C4HN8PS   4.138 
   C3H7N4O2P3   4.424 
 [M-H+ACN]
-
 199.979176 C7H6O3P2   0.205 
   C8N4OS   0.527 
   C8H8S3   1.819 
   H4N6O3S2   2.733 
   H6N6OP2S   3.633 
   C2HN8PS   4.634 





 180.9845 C7H5NOP2   0.756 
   H3N7OS2   2.491 
   CH6N5P3   4.947 





 219.023752 C14H6NP   0.154 
   C4H5N5O6   1.054 
   C6H10N3O2PS   2.823 





 203.049752 C11H10NOP   1.224 
   CH9N5O7   2.195 





 206.036276 C6H10N2O4S   0.721 
   C14H6O2   2.443 
   C8H7N4OP   2.566 
   C8H15PS2   4.842 
242.0141 [M-H]
-
 243.021376 C9H11NO3P2 8.65 1.46 0.166 
   C10H5N5OS   0.43 
   C10H13NS3   1.5 
   C2H9N7O3S2   2.253 
   C2H11N7OP2S   2.986 
   C4H6N9PS   3.817 
   C3H12N5O2P3   4.081 
 [M-H+H2O]
-
 225.010776 C9H9NO2P2   0.336 
   C10H3N5S   0.621 
   C2H7N7O2S2   2.276 
   C2H9N7P2S   3.382 
   C3H10N5OP3   4.251 
 [M-H+ACN]
-
 201.994876 C7H8O3P2   0.044 
   C8H2N4OS   0.274 
   C8H10S3   2.048 
   H6N6O3S2   2.953 
   H8N6OP2S   3.35 





 183.0002 C7H7NOP2   0.475 





 221.039452 C14H8NP   0.073 
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 221.039452 C4H7N5O6   0.819 
   C6H14N3P3   2.737 
   C6H12N3O2PS   3.023 





 205.065452 C11H12NOP   0.968 





 208.051976 C6H12N2O4S   0.954 
   C14H8O2   2.18 
   C8H9N4OP   2.781 
336.0727 [M-H]
-
 337.079976 C10H12N9O3P 15.5 .43 0.284 
   C15H15NO8   0.622 
   C18H16N3PS   0.827 
   C10H20N5O2PS2   1.107 
   C7H21N3O8P2   1.221 
   C8H15N7O6S   1.412 
   C16H19NO3S2   1.955 
   C11H23N3OP4   2.425 
   C7H19N3O10S   2.556 
   C10H22N5P3S   2.67 
   C16H11N5O4   3.346 
   C9H16N5O7P   3.683 
   C9H19N7OS3   3.988 
   C4H21N9OP2S2   4.169 
   C19H17NOP2   4.268 
   C10H12N9O3P   0.284 
 [M-H+H2O]
-
 319.069376 C8H21N3O4S3   0.132 
   C10H10N9O2P   0.411 
   C15H13NO7   0.546 
   C10H18N5OPS2   1.059 
   C9H24NO3P3S   1.26 
   C7H19N3O7P2   1.401 
   C8H13N7O5S   1.602 
   C16H17NO2S2   2.176 
   C11H21N3P4   2.452 
   C7H17N3O9S   2.589 
   C9H26NOP5   2.73 
   C16H9N5O3   3.646 
   C9H14N5O6P   3.781 
   C8H23N3O2P2S2   4.123 
   C4H19N9P2S2   4.294 
   C9H17N7S3   4.324 





 320.053476 C8H20N2O5S3   0.132 
   C10H9N8O3P   0.146 
   C18H13N2PS   0.717 
   C15H12O8   0.808 
   C3H17N10PS3   0.822 
   C7H18N2O8P2   1.133 
   C10H17N4O2PS2   1.319 
   C8H12N6O6S   1.334 
   C9H23O4P3S   1.52 
   C2H13N10O5PS   1.891 
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 320.053476 C16H16O3S2 15.5 .43 1.905 
   C2H15N10O3P3   2.087 
   C9H25O2P5   2.458 
   C10H19N4P3S   2.658 
   C11H20N2OP4   2.708 
   C7H16N2O10S   2.845 
   C16H8N4O4   3.371 
   C8H22N2O3P2S2   3.846 
   C9H13N4O7P   4.033 
   C9H16N6OS3   4.047 
   C4H18N8OP2S2   4.544 
   C19H14OP2   4.649 
 [M-H+ACN]
-
 296.053476 C8H9N8O3P   0.158 
   C16H13N2PS   0.776 
   C13H12O8   0.874 
   C8H17N4O2PS2   1.426 
   C6H12N6O6S   1.442 
   H13N10O5PS   2.044 
   C14H16O3S2   2.06 
   H15N10O3P3   2.256 
   C8H19N4P3S   2.874 
   C9H20N2OP4   2.927 
   C14H8N4O4   3.644 
   C7H13N4O7P   4.36 





 277.0588 C8H8N9OP   0.514 
   C13H11NO6   0.588 
   C8H16N5PS2   1.179 
   C5H17N3O6P2   1.654 
   C6H11N7O4S   1.886 
   C14H15NOS2   2.546 
   C5H15N3O8S   2.941 
   C14H7N5O2   4.239 





 315.098052 C15H9N9   0.125 
   C12H18N3O5P   1.127 
   C14H23NOP2S   1.568 
   C6H19N7O4P2   2.148 
   C10H21NO8S   2.334 
   C5H18N9O3PS   3.303 
   C7H21N7OS3   3.433 
   C13H22N3PS2   3.883 
   C14H13N5O4   4.12 





 299.124052 C12H21N5S2   0.718 
   C12H13N9O   0.849 
   C11H27NO2P2S   0.933 
   C9H22N3O6P   1.905 
   C11H29NP4   3.323 
   C11H17N5O5   3.622 
   C10H26N3OPS2   4.809 
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 302.110576 C14H23O3PS   0.08 
   C6H19N6O6P   0.686 
   C8H26N4P4   0.718 
   C16H20N2P2   1.338 
   C7H23N6OPS2   2.189 
   C12H18N2O7   2.731 
   C9H18N8S2   3.284 
   C24H14   3.395 
   C8H24N4O2P2S   3.496 
   C7H15N10O2P   3.741 
   C14H25OP3   4.134 
338.0879 [M-H]
-
 339.095176 C10H22N5O2PS2 15.52 0 0.227 
   C15H17NO8   0.709 
   C11H25N3OP4   1.084 
   C10H14N9O3P   1.61 
   C18H18N3PS   2.149 
   C9H18N5O7P   2.334 
   C8H17N7O6S   2.731 
   C19H19NOP2   2.916 
   C16H21NO3S2   3.27 
   C10H24N5P3S   3.981 
   C12H17N7OS2   4.649 
   C16H13N5O4   4.653 
   C11H23N3O3P2S   4.838 
 [M-H+H2O]
-
 321.084576 C10H20N5OPS2   0.349 
   C15H15NO7   0.859 
   C11H23N3P4   1.035 
   C7H19N3O9S   1.171 
   C10H12N9O2P   1.81 
   C9H16N5O6P   2.355 
   C7H21N3O7P2   2.794 
   C4H21N9P2S2   2.865 
   C19H17NP2   2.969 
   C8H15N7O5S   2.994 
   C16H19NO2S2   3.564 





 322.068676 C10H19N4O2PS2   0.086 
   C2H15N10O5PS   0.482 
   C15H14O8   0.594 
   C11H22N2OP4   1.294 
   C7H18N2O10S   1.43 
   C10H11N8O3P   1.542 
   C18H15N2PS   2.11 
   C3H19N10PS3   2.215 
   C7H20N2O8P2   2.523 
   C9H15N4O7P   2.61 
   C8H14N6O6S   2.723 
   C4H20N8OP2S2   3.118 
   C19H16OP2   3.222 
   C16H18O3S2   3.291 
   C2H17N10O3P3   3.471 
   C12H6N10O2   3.591 
   C10H21N4P3S   4.039 
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 322.068676 C5H23N6P5   4.498 
   C16H10N4O4   4.747 
 [M-H+ACN]
-
 298.068676 C8H19N4O2PS2   0.093 
   C13H14O8   0.642 
   C9H22N2OP4   1.398 
   C8H11N8O3P   1.667 
   C16H15N2PS   2.28 
   C7H15N4O7P   2.82 
   C6H14N6O6S   2.942 
   C17H16OP2   3.482 
   C14H18O3S2   3.556 
   C10H6N10O2   3.88 





 279.074 C8H18N5PS2   0.443 
   C13H13NO6   1.029 
   C8H10N9OP   2.123 
   C7H14N5O5P   2.669 
   C6H13N7O4S   3.485 





 317.113252 C14H25NOP2S   0.138 
   C6H21N7O4P2   0.715 
   C15H11N9   1.543 
   C7H23N7OS3   1.991 
   C12H20N3O5P   2.539 
   C14H15N5O4   2.674 
   C8H26N5P3S   3.393 
   C10H23NO8S   3.738 
   C14H23NO3S2   4.153 
   C5H20N9O3PS   4.701 





 301.139252 C12H23N5S2   0.781 
   C11H19N5O5   2.103 
   C12H15N9O   2.338 
   C9H24N3O6P   3.387 





 304.125776 C16H22N2P2   0.15 
   C6H21N6O6P   0.799 
   C14H25O3PS   1.4 
   C9H20N8S2   1.782 
   C24H16   1.892 
   C16H20N2O2S   4.036 
   C12H20N2O7   4.192 
   C8H16N8O5   4.637 
377.1822 [M-H]
-
 378.189476 C20H31N2OPS 20.89 0.02 0.014 
   C12H27N8O4P   0.497 
   C18H34O4S2   0.991 
   C17H30O9   1.305 
   C18H26N4O5   2.232 
   C14H32N6P2S   2.743 
   C11H26N10O3S   4.044 
   C18H36O2P2S   4.358 
   C22H26N4S   4.385 
 [M-H+H2O]
-
 360.178876 C20H29N2PS   0.084 
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 360.178876 C12H25N8O3P   0.424 
   C10H28N6O6S   0.631 
   C18H32O3S2   1.139 
   C17H28O8   1.272 
   C18H24N4O4   2.441 
   C11H29N4O7P   4.137 
   C10H30N6O4P2   4.166 





 361.162976 C20H28NOPS   0.15 
   C10H27N5O7S   0.396 
   C12H24N7O4P   0.657 
   C18H23N3O5   2.201 
   C14H29N5P2S   3.008 
   C10H29N5O5P2   3.921 
   C11H23N9O3S   4.099 
   C11H28N3O8P   4.36 
   C19H27N3S2   4.605 
 [M-H+ACN]
-
 337.162976 C18H28NOPS   0.161 
   C10H24N7O4P   0.703 
   C16H23N3O5   2.358 
   C12H29N5P2S   3.222 
   C9H23N9O3S   4.391 





 318.1683 C10H23N8O2P   0.445 
   C16H30O2S2   1.325 
   C15H26O7   1.404 
   C16H22N4O3   2.799 





 356.207552 C14H33N2O6P   0.2 
   C17H24N8O   0.687 
   C9H30N10OP2   1.057 
   C17H32N4S2   2.003 
   C9H28N10O3S   2.517 
   C15H29N6O2P   3.955 





 340.233552 C14H28N8O2   0.088 
   C13H32N4O6   4.018 
   C23H33P   4.598 





 343.220076 C18H35NOP2   2.005 
   C9H30N9O3P   2.466 




Known Metabolites Found In Zyflamend Treated and Control Samples and PLS-
DA Variates and Loadings 
Table S9.  Zyflamend: Known Metabolites and Average Log2 Peak Area Ratios for 










sn-glycerol-3-phosphate(-,***,-,-,-) -0.3425 -0.5655 0.1091 NA -0.2904 
phenylalanine(-,***,-,-,-) 0.2470 -0.3175 0.2584 -0.2311 2.3065 
Methionine sulfoxide(*,***,-,-,-) 0.5582 -1.0388 NA NA NA 
lysine(-,***,-,*,-) -0.0276 -0.4902 0.2404 -0.3749 NA 
threonine(-,***,-,-,-) 0.1010 -0.4028 0.1478 -0.5191 NA 
homoserine(-,***,-,-,-) NA -0.4028 0.1508 -0.5191 NA 
proline(-,***,-,*,-) -0.0540 -0.5350 0.3055 -0.7131 NA 
tyrosine(-,***,-,-,-) 0.3272 -0.3553 0.0099 -0.3656 1.1020 
valine(-,***,-,-,-) 0.1637 -0.2833 0.0659 -0.2346 1.3799 
leucine/isoleucine(-,**,-,-,-) NA -0.3280 0.2571 -0.2488 2.3698 
arginine(-,**,-,-,-) NA -0.3887 NA NA NA 
xanthine(-,**,**,***,-) -0.1990 -3.5339 0.9109 -1.4292 NA 
Methionine(-,**,-,-,-) 0.3188 -0.2920 0.0882 -0.2299 1.5616 
asparagine(-,**,-,-,-) 0.0333 -0.4072 NA NA NA 
aconitate(-,**,***,-,-) 0.5999 -0.2563 -0.8371 0.7312 0.3152 
serine(-,**,-,-,-) -0.8810 -0.4047 0.2851 NA NA 
histidine(-,**,-,-,-) -0.1672 -0.3324 -0.0494 NA NA 
inosine(-,**,**,**,-) NA -4.3616 1.2055 -1.3174 1.0034 
dihydroxy-acetone-phosphate(-,*,-,*,-) NA -1.1388 0.3136 -1.2634 0.0735 
2-Hydroxy-2-methylbutanedioic acid(-
,*,-,-,-) 0.3224 -0.2506 -0.3023 0.0206 -0.4113 
GMP(-,*,-,-,-) -0.2446 1.3527 -0.1173 NA -0.2753 
2-dehydro-D-gluconate(-,*,-,-,-) NA 0.2071 0.1192 NA NA 
dGMP(-,*,-,-,-) NA 2.5276 -0.0369 0.1452 -0.1028 
AMP(*,*,-,-,-) NA 2.5276 -0.0368 0.1452 NA 
Ascorbic acid(-,-,***,-,-) -0.6355 7.0708 -0.3248 -0.0460 -1.0711 
citrate/isocitrate(-,-,**,-,-) 0.3008 -0.2910 -0.7308 0.0326 NA 
uridine(-,-,**,-,-) NA -0.1690 1.7873 -0.2627 1.3082 
2-keto-isovalerate(-,-,-,-,-) 0.3632 0.1414 NA NA NA 
tryptophan(-,-,-,-,-) 0.5999 -0.1089 0.0691 -0.1145 2.1343 
glutamate(-,-,-,-,-) -0.0160 -0.2731 -0.1796 -0.0178 0.1212 
phosphoenolpyruvate(-,-,-,-,-) NA -1.2478 NA NA NA 
citrulline(-,-,-,*,-) NA -0.1497 -0.2995 -0.2748 NA 
N-acetyl-glutamate(-,-,-,**,-) NA -0.3797 -0.2617 0.8303 0.3797 
Kynurenic acid(-,-,-,-,-) 0.4061 -0.4964 NA NA NA 
a-ketoglutarate(-,-,-,-,-) 0.1944 -0.1908 -0.3718 0.1164 0.5866 
3-phosphoglycerate(-,-,-,-,-) -0.0478 -0.7397 0.5208 NA -0.1695 
alanine(-,-,-,-,-) 0.2525 -0.2689 NA NA NA 
trehalose/sucrose(-,-,-,-,-) 0.1951 0.3688 -0.2596 -2.9830 NA 
IMP(-,-,-,**,-) 0.3568 1.0725 0.0069 -0.9260 -0.2811 
Uric acid(-,-,-,-,-) NA -0.2174 1.4043 -0.1581 4.3315 
D-sedoheptulose-1/7-phosphate(-,-,-,-
,-) 0.6146 -0.8136 0.4488 NA NA 
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glutamine(-,-,-,-,-) -0.1062 0.0674 0.1264 -0.1626 NA 
glutathione(-,-,**,-,-) NA 0.3143 -0.2222 0.2660 -0.2490 
N-carbamoyl-L-aspartate(-,-,-,-,-) -0.0166 1.4582 2.7968 NA NA 
pyruvate(-,-,-,-,-) NA -0.0660 NA NA -0.1846 
6-phospho-D-gluconate(-,-,-,-,-) 0.2349 -0.6643 NA NA NA 
guanosine(-,-,*,-,-) 1.1089 0.4822 0.6068 NA NA 
Aminoadipic acid(-,-,-,-,-) -0.1864 -0.1552 -0.4065 NA NA 
indole(-,-,-,-,-) 1.0440 -0.0786 NA NA NA 
Xanthurenic acid(*,-,-,-,-) 1.6556 -0.4510 NA NA NA 
Pyroglutamic acid(-,-,-,***,-) 0.1348 0.1752 -0.0479 -0.5749 NA 
allantoin(*,-,-,-,-) -0.3064 -0.1124 -0.0852 -0.0499 NA 
succinate(*,-,-,-,-) 0.8990 0.1781 0.0141 0.0752 -0.1528 
Methylmalonic acid(-,-,-,-,-) -0.2300 0.1781 0.0103 NA -0.1532 
malate(-,-,-,-,-) -0.1300 -0.2006 NA NA 0.1878 
2_3-Diphosphoglyceric acid(-,-,-,-,-) -0.1736 -0.2720 NA NA NA 
glucose-6-phosphate(*,-,*,-,-) 0.6580 -0.1750 0.5704 NA 0.3067 
N-acetyl-glutamine(-,-,-,-,-) NA 0.0873 -0.0717 0.1133 NA 
uracil(-,-,**,-,-) 1.4111 0.1680 0.8373 -0.4762 5.0107 
Taurine(-,-,-,-,-) 1.1610 -0.0409 0.1324 0.1465 0.0875 
cytidine(-,-,-,***,-) 0.9619 0.0941 NA -0.6589 0.4700 
orotate(-,-,-,-,*) NA 0.0683 2.2214 -0.1209 2.0320 
IDP(-,-,-,-,-) NA -0.0351 NA NA NA 
lactate(-,-,-,-,-) 0.1976 0.0128 0.0433 NA 0.1216 
glutathione disulfide(-,-,**,-,-) NA -0.0060 -0.3163 0.1477 -0.1289 
Taurodeoxycholic acid(*,-,-,-,-) 0.6715 NA -0.7130 NA NA 
Cysteate(*,-,**,-,-) 0.2039 NA -0.9705 NA NA 
guanine(*,-,***,-,-) 0.6580 NA 1.2241 NA NA 
p-hydroxybenzoate(*,-,-,-,-) -0.1977 NA NA -1.7090 NA 
UDP(-,-,-,-,-) 0.3626 NA 0.1803 NA NA 
hypoxanthine(-,-,-,**,-) 0.1577 NA NA -3.0368 NA 
CMP(-,-,-,***,-) 0.3594 NA 0.1121 -0.7726 NA 
UDP-D-glucuronate(-,-,-,-,-) -0.1840 NA 0.2118 NA NA 
NADH(-,-,-,**,-) 1.1155 NA -0.3646 0.8207 0.1543 
xanthosine(-,-,*,-,-) 3.7199 NA 2.5684 NA NA 
UDP-D-glucose(-,-,-,-,-) 0.1566 NA -0.0568 -0.0143 0.3302 
UDP-N-acetyl-glucosamine(-,-,-,-,-) 1.1997 NA 0.1687 -0.1579 -0.3827 
glucose-1-phosphate(-,-,*,-,-) 0.1208 NA 0.5703 NA NA 
ADP(-,-,*,-,-) -0.3146 NA -0.3833 NA -0.3186 
adenosine(-,-,-,-,-) -0.0550 NA 0.3947 -0.1812 NA 
aspartate(-,-,-,-,-) -0.1047 NA 0.0212 0.0153 1.0163 
fumarate(-,-,-,*,-) -0.0392 NA -0.1809 -0.8382 0.3757 
pantothenate(-,-,-,-,-) -0.0296 NA -0.3110 0.1706 0.5666 
NAD+(-,-,-,***,-) -0.0166 NA -0.3445 1.3483 -0.0152 
UMP(-,-,*,**,-) NA NA 0.7252 -0.4100 -0.2504 
sarcosine(-,-,-,-,-) NA NA NA NA 0.2505 
FAD(-,-,-,-,-) NA NA -0.2042 NA -0.1258 
myo-inositol(-,-,-,-,-) NA NA NA -0.0625 0.1117 
D-glyceraldehdye-3-phosphate(-,-,-,*,-
) NA NA 0.3120 -1.2634 NA 
CDP-ethanolamine(-,-,-,-,-) NA NA 0.2559 0.2587 NA 
pyridoxine(-,-,*,-,-) NA NA -1.5170 NA NA 
homocysteic acid(-,-,*,-,-) NA NA -1.6709 NA NA 
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S-adenosyl-L-methioninamine(-,-,-,-,-) NA NA -0.3091 NA NA 
Cystine(-,-,-,-,-) NA NA -0.1800 NA NA 
3-methylphenylacetic acid(-,-,-,-,-) NA NA 0.5606 NA NA 
S-adenosyl-L-homoCysteine(-,-,-,-,-) NA NA 0.1798 NA NA 
Sulfolactate(-,-,-,-,-) NA NA -0.1026 NA NA 
D-gluconate(-,**,-,-,-) -0.0723 0.3078 0.2405 -0.2896 NA 
 






















P value   
(8 weeks) 
phenylalanine 7.34E+06 6.73E+06 0.442 7.15E+06 6.43E+06 0.279 
threonine 2.63E+06 2.38E+06 0.647 2.56E+06 2.52E+06 0.942 
homoserine 2.53E+06 2.25E+06 0.616 2.42E+06 2.41E+06 0.986 
proline 3.33E+06 3.11E+06 0.661 2.92E+06 3.01E+06 0.831 
tyrosine 5.53E+06 4.90E+06 0.394 4.94E+06 4.72E+06 0.634 
valine 7.79E+06 7.98E+06 0.839 8.02E+06 8.14E+06 0.879 
leucine/isoleucine 8.56E+06 8.62E+06 0.963 9.15E+06 8.94E+06 0.848 
Methionine 1.47E+06 1.18E+06 0.168 1.41E+06 1.21E+06 0.154 
asparagine 1.60E+05 1.53E+05 0.851 1.67E+05 1.70E+05 0.925 
serine 4.32E+05 4.32E+05 0.997 4.36E+05 4.87E+05 0.575 
tryptophan 4.49E+06 4.57E+06 0.902 3.81E+06 4.49E+06 0.194 
citrulline 4.82E+05 5.38E+05 0.595 5.28E+05 5.55E+05 0.812 
Uric acid 5.60E+07 5.32E+07 0.719 6.35E+07 5.19E+07 0.162 
glutamine 1.75E+07 1.81E+07 0.761 1.86E+07 1.87E+07 0.968 
pyruvate 1.28E+07 1.47E+07 0.472 1.20E+07 1.69E+07 0.185 
Pyroglutamic acid 2.80E+06 3.20E+06 0.314 3.33E+06 3.10E+06 0.652 
succinate 1.62E+06 2.06E+06 0.167 1.89E+06 1.88E+06 0.977 
Taurine 1.31E+06 1.27E+06 0.885 1.35E+06 1.35E+06 0.994 
aspartate 3.33E+06 4.11E+06 0.651 5.52E+06 4.77E+06 0.725 
S-adenosyl-L-
methioninamine 
1.60E+05 1.91E+05 0.470 1.87E+05 2.01E+05 0.782 
Cystine 8.74E+05 9.53E+05 1.01E+06 1.01E+06 1.01E+06 0.992 




Table S11.  Zyflamend: PLS-DA Mouse Plasma (0 and 4 weeks) Variates 
Mouse Plasma Sample X.comp.1 X.comp.2 Y.comp.1 Y.comp.2 
Control 0 weeks 1 5.935 -0.080 1.093 0.014 
Control 0 weeks 2 6.580 0.197 1.093 0.011 
Control 0 weeks 3 6.418 0.152 1.093 0.011 
Control 0 weeks 4 6.202 0.048 1.093 0.013 
Control 0 weeks 5 6.340 -0.038 1.093 0.012 
Control 0 weeks 6 6.201 0.275 1.093 0.013 
Control 0 weeks 7 6.367 0.068 1.093 0.012 
Control 0 weeks 8 6.309 -0.053 1.093 0.012 
Control 0 weeks 9 6.573 0.086 1.093 0.011 
Control 0 weeks 10 7.001 0.002 1.093 0.008 
Control 0 weeks 11 6.037 0.064 1.093 0.014 
Control 0 weeks 12 6.290 -0.230 1.093 0.012 
Control 0 weeks 13 6.182 0.107 1.093 0.013 
Control 4 weeks 1 -6.546 -1.576 -1.214 -1.593 
Control 4 weeks 2 -8.606 -0.259 -1.214 -1.582 
Control 4 weeks 3 -7.208 -0.996 -1.214 -1.590 
Control 4 weeks 4 -6.284 -3.101 -1.214 -1.595 
Control 4 weeks 5 -6.277 -1.119 -1.214 -1.595 
Control 4 weeks 6 -7.317 -3.650 -1.214 -1.589 
Control 4 weeks 7 -6.693 -1.354 -1.214 -1.593 
Control 4 weeks 8 -6.793 -0.633 -1.214 -1.592 
Control 4 weeks 9 -8.435 0.920 -1.214 -1.583 
Control 4 weeks 10 -7.271 -0.853 -1.214 -1.589 
Control 4 weeks 11 -6.457 -3.364 -1.214 -1.594 
Control 4 weeks 12 -6.805 -3.647 -1.214 -1.592 
Control 4 weeks 13 -5.705 -1.093 -1.214 -1.598 
Zyflamend 0 weeks 1 6.827 0.013 1.149 -0.077 
Zyflamend 0 weeks 2 6.214 -0.042 1.149 -0.074 
Zyflamend 0 weeks 3 6.224 0.022 1.149 -0.074 
Zyflamend 0 weeks 4 6.666 0.157 1.149 -0.076 
Zyflamend 0 weeks 5 6.333 0.284 1.149 -0.074 
Zyflamend 0 weeks 6 6.888 -0.077 1.149 -0.078 
Zyflamend 0 weeks 7 6.920 -0.072 1.149 -0.078 
Zyflamend 0 weeks 8 5.984 -0.067 1.149 -0.072 
Zyflamend 0 weeks 9 7.072 -0.079 1.149 -0.079 
Zyflamend 0 weeks 10 6.964 -0.046 1.149 -0.078 
Zyflamend 0 weeks 11 6.610 -0.228 1.149 -0.076 
Zyflamend 0 weeks 12 6.135 -0.094 1.149 -0.073 
Zyflamend 0 weeks 13 6.131 -0.235 1.149 -0.073 
Zyflamend 0 weeks 14 5.995 -0.060 1.149 -0.073 
Zyflamend 4 weeks 1 -6.547 2.210 -1.116 1.661 
Zyflamend 4 weeks 2 -8.529 3.947 -1.116 1.672 
Zyflamend 4 weeks 3 -5.963 0.632 -1.116 1.658 
Zyflamend 4 weeks 4 -4.812 -0.139 -1.116 1.652 
Zyflamend 4 weeks 5 -6.760 0.212 -1.116 1.662 
Zyflamend 4 weeks 6 -8.363 0.612 -1.116 1.671 
Zyflamend 4 weeks 7 -7.076 0.955 -1.116 1.664 
Zyflamend 4 weeks 8 -5.830 1.604 -1.116 1.657 
Zyflamend 4 weeks 9 -5.651 1.827 -1.116 1.656 
Zyflamend 4 weeks 10 -6.003 3.994 -1.116 1.658 
Zyflamend 4 weeks 11 -5.542 0.002 -1.116 1.656 
Zyflamend 4 weeks 12 -6.826 3.096 -1.116 1.663 
Zyflamend 4 weeks 13 -5.098 1.699 -1.116 1.653 
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Table S12.  Zyflamend: PLS-DA Mouse (0 and 4 weeks) Plasma Loadings 
Compound comp 1 comp 2 
NAD. 0.1496 -0.0261 
pantothenate 0.1492 -0.0261 
fumarate 0.1491 -0.0259 
UDP.D.glucose 0.1486 -0.0268 
glucose.1.phosphate 0.1472 -0.0264 
aspartate 0.1445 -0.0250 
Pyroglutamic.acid 0.1400 -0.0042 
guanine 0.1386 -0.0280 
glucose.6.phosphate 0.1262 -0.0315 
NADH 0.1235 -0.0254 
ADP 0.1211 -0.0191 
UDP.N.acetyl.glucosamine 0.0722 -0.0176 
X3.phosphoglycerate 0.0128 -0.1825 
IMP -0.0359 0.3176 
Ascorbic.acid -0.0417 0.3417 
GMP -0.0592 0.3761 
xanthine -0.0636 -0.3421 
AMP -0.0682 0.3367 
dGMP -0.0682 0.3367 
inosine -0.0711 -0.3388 
X2.Hydroxy.2.methylbutanedioic.acid -0.1204 -0.1132 
dihydroxy.acetone.phosphate -0.1293 -0.1794 
X2_3.Diphosphoglyceric.acid -0.1313 -0.0396 
glutathione.disulfide -0.1336 0.0439 
malate -0.1362 -0.0226 
succinate -0.1386 0.0763 
allantoin -0.1407 -0.0052 
Methylmalonic.acid -0.1413 0.0728 
orotate -0.1413 0.0053 
glutathione -0.1418 0.0888 
N.acetyl.glutamate -0.1420 -0.0545 
lactate -0.1428 0.0356 
sn.glycerol.3.phosphate -0.1458 -0.1181 
Uric.acid -0.1459 -0.0231 
tyrosine -0.1460 -0.0826 
glutamate -0.1463 -0.0305 
proline -0.1464 -0.0987 
citrate.isocitrate -0.1469 -0.0334 
N.acetyl.glutamine -0.1470 0.0381 
serine -0.1472 -0.0585 
a.ketoglutarate -0.1475 -0.0157 
D.gluconate -0.1485 0.0952 
threonine -0.1486 -0.0641 
Taurine -0.1487 0.0192 
homoserine -0.1490 -0.0593 
Methionine -0.1491 -0.0440 
valine -0.1495 -0.0476 
leucine.isoleucine -0.1495 -0.0441 
aconitate -0.1496 -0.0283 
citrulline -0.1497 -0.0068 
X2.keto.isovalerate -0.1500 0.0567 
phenylalanine -0.1501 -0.0462 
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Table S12. Continued 
Compound comp 1 comp 2 
tryptophan -0.1505 0.0025 
glutamine -0.1506 0.0413 
pyruvate -0.1507 0.0110 
uridine -0.1501 -0.0092 
 
 
Table S13.  Zyflamend: PLS-DA Known Mouse Adipose Variates 
Mouse Adipose 
Sample 
X.comp.1 X.comp.2 Y.comp.1 Y.comp.2 
Control 1 9.705 -4.167 1.387 -1.924 
Control 2 2.601 -0.789 1.387 0.499 
Control 3 3.892 5.083 1.387 0.059 
Control 4 1.945 3.912 1.387 0.723 
Control 5 0.766 -2.640 1.387 1.125 
Control 6 0.306 4.444 1.387 1.282 
Control 7 1.348 2.054 1.387 0.927 
Control 8 2.856 -2.237 1.387 0.413 
Control 9 0.984 5.503 1.387 1.051 
Control 10 0.907 1.871 1.387 1.077 
Control 11 -1.046 4.515 1.387 1.743 
Control 12 1.542 2.637 1.387 0.861 
Control 13 -1.176 -1.157 1.387 1.788 
Zyflamend 1 1.183 -5.004 -1.387 -1.790 
Zyflamend 2 -2.373 0.094 -1.387 -0.577 
Zyflamend 3 -1.957 -0.906 -1.387 -0.719 
Zyflamend 4 -3.210 -0.878 -1.387 -0.292 
Zyflamend 5 -0.653 -6.279 -1.387 -1.164 
Zyflamend 6 -1.356 -3.242 -1.387 -0.924 
Zyflamend 7 -2.595 -2.048 -1.387 -0.502 
Zyflamend 8 -1.857 -5.985 -1.387 -0.753 
Zyflamend 9 -2.166 5.061 -1.387 -0.648 
Zyflamend 10 -2.915 0.166 -1.387 -0.392 
Zyflamend 11 -1.450 -1.820 -1.387 -0.892 
Zyflamend 12 -2.979 -1.755 -1.387 -0.371 




Table S14.  Zyflamend: PLS-DA Known Mouse Adipose Loadings 
Compound comp 1 comp 2 
xanthine 0.3030 0.0128 
Pyroglutamic.acid 0.2949 0.0372 
IMP 0.2455 -0.0285 
inosine 0.2365 -0.0969 
UMP 0.2267 0.0561 
dihydroxy.acetone.phosphate 0.2070 -0.0844 
proline 0.2025 -0.0539 
fumarate 0.1787 -0.0698 
citrulline 0.1771 -0.0961 
homoserine 0.1767 -0.1297 
threonine 0.1767 -0.1297 
tyrosine 0.1264 -0.1707 
Methionine 0.1046 -0.1672 
valine 0.0978 -0.2002 
glutamine 0.0906 -0.1981 
D.gluconate 0.0854 -0.1439 
phenylalanine 0.0849 -0.1940 
leucine.isoleucine 0.0682 -0.2348 
uridine 0.0678 -0.2104 
UDP.N.acetyl.glucosamine 0.0633 -0.2016 
Uric.acid 0.0487 -0.1730 
Ascorbic.acid 0.0410 -0.1061 
tryptophan 0.0367 -0.1747 
allantoin 0.0197 -0.1218 
myo.inositol 0.0183 -0.1294 
UDP.D.glucose 0.0127 -0.1628 
citrate.isocitrate 0.0058 -0.0935 
glutamate 0.0056 -0.2014 
aspartate -0.0113 -0.1534 
orotate -0.0155 -0.1050 
X2.Hydroxy.2.methylbutanedioic.acid -0.0157 -0.2295 
N.acetyl.glutamine -0.0355 -0.1951 
AMP -0.0413 -0.0147 
dGMP -0.0413 -0.0147 
succinate -0.0416 -0.2562 
a.ketoglutarate -0.0505 -0.1490 
aconitate -0.0904 -0.0833 
glutathione.disulfide -0.1049 -0.1910 
pantothenate -0.1195 -0.0816 
glutathione -0.1307 -0.0981 
Taurine -0.1507 -0.1673 
N.acetyl.glutamate -0.2270 -0.0968 
NADH -0.2618 -0.2204 





Table S15.  Zyflamend: PLS-DA Known Liver Variates 
Mouse Liver 
Sample 
X.comp.1 X.comp.2 Y.comp.1 Y.comp.2 
Control 1 2.056 4.245 1.468 0.652 
Control 2 2.525 -0.858 1.468 0.466 
Control 3 1.956 3.135 1.468 0.692 
Control 4 3.444 3.496 1.468 0.101 
Control 5 5.130 -2.899 1.468 -0.568 
Control 6 2.536 0.768 1.468 0.461 
Zyflamend 1 -0.093 -6.000 -1.258 -1.221 
Zyflamend 2 -4.163 4.075 -1.258 0.394 
Zyflamend 3 -1.211 -3.182 -1.258 -0.778 
Zyflamend 4 -3.391 0.721 -1.258 0.087 
Zyflamend 5 -1.386 -4.775 -1.258 -0.708 
Zyflamend 6 -4.830 0.067 -1.258 0.658 
Zyflamend 7 -2.574 1.206 -1.258 -0.237 
 
Table S16.  Zyflamend: PLS-DA Known Liver Loadings 
Compound comp 1 comp 2 
aconitate 0.2696 -0.0210 
Ascorbic.acid 0.2688 0.1726 
citrate.isocitrate 0.2333 -0.0220 
glutathione 0.2088 0.2059 
glutathione.disulfide 0.2044 0.0347 
NAD. 0.1802 0.1158 
ADP 0.1797 0.1680 
citrulline 0.1358 0.1839 
pantothenate 0.1336 0.1988 
fumarate 0.1308 0.2598 
X2.Hydroxy.2.methylbutanedioic.acid 0.1255 -0.0146 
a.ketoglutarate 0.1236 0.0450 
N.acetyl.glutamate 0.1191 0.0113 
FAD 0.1167 0.1461 
NADH 0.1029 -0.0031 
glutamate 0.0772 -0.0255 
N.acetyl.glutamine 0.0612 0.1748 
GMP 0.0408 0.2086 
UDP.D.glucose 0.0359 0.1088 
allantoin 0.0344 0.2785 
Pyroglutamic.acid 0.0267 0.1673 
IMP 0.0145 0.0636 
dGMP 0.0140 0.1785 
AMP 0.0140 0.1784 
Cystine 0.0005 -0.0510 
aspartate -0.0038 0.1195 
Methylmalonic.acid -0.0058 -0.0263 
succinate -0.0073 -0.0284 
tyrosine -0.0122 0.2144 
lactate -0.0178 0.1511 
UDP.N.acetyl.glucosamine -0.0422 0.1442 
tryptophan -0.0436 0.1666 
sn.glycerol.3.phosphate -0.0488 0.0805 
   
 92 
Table S16. Continued 
Compound comp 1 comp 2 
valine -0.0526 0.0991 
Methionine -0.0570 0.1832 
orotate -0.0747 0.0307 
dihydroxy.acetone.phosphate -0.0815 0.2069 
X3.phosphoglycerate -0.0821 0.1201 
glutamine -0.0904 0.1032 
threonine -0.1026 0.1136 
homoserine -0.1046 0.1133 
Taurine -0.1057 0.1191 
phenylalanine -0.1112 0.1670 
serine -0.1181 0.0926 
leucine.isoleucine -0.1367 0.1416 
D.gluconate -0.1427 0.0891 
proline -0.1473 0.0996 
UMP -0.1562 0.1535 
Uric.acid -0.1669 0.1216 
glucose.6.phosphate -0.1729 0.0736 
glucose.1.phosphate -0.1729 0.0736 
xanthine -0.1984 0.1163 
uridine -0.2295 0.0876 
inosine -0.2503 0.0760 
guanine -0.2938 -0.1217 
   
   
 
Table S17.  Zyflamend: PLS-DA Known Human Plasma Variates 
Human Plasma Sample X.comp.1 X.comp.2 Y.comp.1 Y.comp.2 
Control 0 weeks 1 2.397 -2.455 1.187 0.764 
Control 0 weeks 2 0.006 -0.113 1.187 1.747 
Control 0 weeks 3 0.403 1.908 1.187 1.584 
Control 0 weeks 4 1.593 -2.763 1.187 1.095 
Control 0 weeks 5 0.734 3.943 1.187 1.448 
Control 0 weeks 6 1.508 0.159 1.187 1.130 
Control 0 weeks 7 1.899 0.296 1.187 0.969 
Control 0 weeks 8 0.801 -1.899 1.187 1.421 
Control 0 weeks 9 0.445 1.717 1.187 1.567 
Control 0 weeks 10 1.121 -0.273 1.187 1.289 
Control 0 weeks 11 1.420 2.215 1.187 1.166 
Control 0 weeks 12 0.817 -2.201 1.187 1.414 
Control 0 weeks 13 -0.804 3.078 1.187 2.080 
Control 0 weeks 14 -0.541 4.224 1.187 1.972 
Control 0 weeks 15 -0.232 1.009 1.187 1.845 
Control 0 weeks 16 0.809 3.457 1.187 1.417 
Control 0 weeks 17 -0.790 -2.850 1.187 2.075 
Control 0 weeks 18 -1.070 2.293 1.187 2.190 
Control 0 weeks 19 -0.694 4.305 1.187 2.035 
Control 0 weeks 20 -0.824 -3.690 0.996 0.343 
Control 8 weeks 3.154 1.044 0.996 -1.292 
Control 8 weeks 0.781 0.529 0.996 -0.316 
Control 8 weeks -0.029 -0.845 0.996 0.016 
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Table S17. Continued 
Human Plasma Sample X.comp.1 X.comp.2 Y.comp.1 Y.comp.2 
Control 8 weeks 1.725 -1.466 0.996 -0.705 
Control 8 weeks 2.011 0.405 0.996 -0.822 
Control 8 weeks 0.477 1.673 0.996 -0.191 
Control 8 weeks 1.605 1.495 0.996 -0.655 
Control 8 weeks -0.781 -1.948 0.996 0.326 
Control 8 weeks 0.396 1.060 0.996 -0.158 
Control 8 weeks 1.554 0.237 0.996 -0.634 
Control 8 weeks 0.505 0.589 0.996 -0.203 
Control 8 weeks -0.221 0.488 0.996 0.096 
Control 8 weeks 0.057 0.313 0.996 -0.019 
Control 8 weeks -0.366 0.343 0.996 0.155 
Control 8 weeks -1.203 -0.845 0.996 0.499 
Control 8 weeks -1.150 0.849 0.996 0.477 
Zyflamend 0 weeks -0.669 1.046 -1.190 -0.846 
Zyflamend 0 weeks 0.720 -4.871 -1.190 -1.418 
Zyflamend 0 weeks -0.111 0.825 -1.190 -1.076 
Zyflamend 0 weeks -0.844 1.645 -1.190 -0.775 
Zyflamend 0 weeks -0.914 1.219 -1.190 -0.746 
Zyflamend 0 weeks -0.652 -2.260 -1.190 -0.854 
Zyflamend 0 weeks -1.548 -1.584 -1.190 -0.485 
Zyflamend 0 weeks -0.241 -3.205 -1.190 -1.023 
Zyflamend 0 weeks -1.160 -0.370 -1.190 -0.645 
Zyflamend 0 weeks 1.347 -0.247 -1.190 -1.676 
Zyflamend 0 weeks -1.123 -0.764 -1.190 -0.660 
Zyflamend 0 weeks -0.258 -0.930 -1.190 -1.016 
Zyflamend 0 weeks -0.868 0.753 -1.190 -0.765 
Zyflamend 0 weeks 0.179 -0.472 -1.190 -1.195 
Zyflamend 0 weeks -0.201 1.061 -1.190 -1.039 
Zyflamend 0 weeks -0.880 -0.147 -1.190 -0.760 
Zyflamend 0 weeks -1.666 -0.960 -1.190 -0.437 
Zyflamend 8 weeks -0.126 2.313 -1.203 -0.839 
Zyflamend 8 weeks -1.483 -5.152 -1.203 -0.281 
Zyflamend 8 weeks -0.597 -0.669 -1.203 -0.646 
Zyflamend 8 weeks -0.474 0.992 -1.203 -0.696 
Zyflamend 8 weeks 0.268 -4.252 -1.203 -1.001 
Zyflamend 8 weeks 1.242 -2.259 -1.203 -1.402 
Zyflamend 8 weeks -0.442 0.883 -1.203 -0.709 
Zyflamend 8 weeks 1.155 1.428 -1.203 -1.366 
Zyflamend 8 weeks 0.546 -1.088 -1.203 -1.115 
Zyflamend 8 weeks -1.741 -3.689 -1.203 -0.175 
Zyflamend 8 weeks -1.057 -4.042 -1.203 -0.457 
Zyflamend 8 weeks -0.919 2.202 -1.203 -0.513 
Zyflamend 8 weeks -0.587 -2.898 -1.203 -0.650 
Zyflamend 8 weeks -1.866 4.379 -1.203 -0.124 
Zyflamend 8 weeks -0.476 2.625 -1.203 -0.695 




Table S18.  Zyflamend: PLS-DA Known Human Plasma Loadings 
Compound comp 1 comp 2 
D.gluconate 0.5200 -0.0811 
Methionine 0.4150 -0.1130 
phenylalanine 0.3103 -0.2222 
tyrosine 0.2521 -0.1612 
Uric.acid 0.2420 -0.3013 
homoserine 0.1477 0.0031 
proline 0.1336 -0.1573 
threonine 0.1323 -0.0251 
Taurine 0.0407 -0.0035 
leucine.isoleucine 0.0004 -0.3802 
glutamine -0.0221 -0.1577 
aspartate -0.0585 -0.2115 
Cystine -0.0674 -0.2427 
valine -0.0849 -0.3590 
serine -0.1076 0.0201 
Pyroglutamic.acid -0.1226 -0.4721 
citrulline -0.1588 -0.1230 
tryptophan -0.1853 -0.0819 
succinate -0.2624 -0.3411 
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505.208 18.2 -0.104 0.885 2.589 0.000 -5.010 0.337 14.896 0.337 
508.2269 18.1 0.878 0.367 3.218 0.009 0.665 0.595 5.969 0.595 
507.2234 18.2 0.852 0.389 3.103 0.007 1.096 0.621 8.712 0.621 
509.2314 18.1 0.893 0.350 3.136 0.013 0.000 - 5.001 - 
310.1509 1.9 -0.349 0.560 -1.113 0.039 -0.417 0.193 -0.582 0.193 
330.0336 13.8 0.294 0.185 -0.429 0.049 -0.621 0.488 -2.566 0.488 
200.0543 1.2 -0.029 0.883 -0.422 0.018 -0.121 0.302 -0.369 0.302 
309.068 1.1 0.105 0.607 -0.471 0.030 -0.148 0.282 0.186 0.282 
292.084 16.7 0.105 0.770 -0.747 0.040 0.185 0.526 0.117 0.526 
124.991 5.6 -0.097 0.759 -0.823 0.037 0.280 0.368 0.478 0.368 
281.0991 1.2 -0.082 0.866 -1.194 0.037 1.691 0.000 0.569 0.000 
258.1573 5.6 -0.264 0.521 -0.897 0.017 0.016 0.836 0.368 0.836 
329.03 14.0 0.250 0.158 -0.432 0.026 0.194 0.482 0.174 0.482 
506.2108 18.2 -0.451 0.664 2.764 0.000 -5.027 0.337 -4.737 0.337 
345.0043 10.3 -0.100 0.920 -3.046 0.047 0.480 0.269 0.453 0.269 
227.0648 1.2 0.033 0.819 -0.358 0.023 -0.151 0.140 0.092 0.140 
187.0011 6.4 0.133 0.690 1.221 0.039 0.514 0.050 0.288 0.050 
583.1746 15.2 0.039 0.930 -0.884 0.034 -0.344 0.801 -1.297 0.801 
206.01 1.2 -0.026 0.894 -0.464 0.013 0.068 0.541 0.107 0.541 
523.2189 17.3 -0.333 0.687 3.920 0.009 -0.964 0.567 -1.435 0.567 
351.0114 14.1 0.240 0.291 -0.481 0.043 0.101 0.698 0.145 0.698 
89.03577 6.1 -0.387 0.354 1.303 0.036 0.575 0.023 -0.217 0.023 
152.9957 6.2 0.493 0.562 1.585 0.047 -0.308 0.820 -0.885 0.820 
261.0588 1.2 -0.251 0.312 -0.583 0.007 -0.195 0.356 -0.093 0.356 
90.02714 6.0 -0.498 0.222 0.911 0.050 0.307 0.143 -0.114 0.143 
321.0806 1.1 -0.172 0.569 -0.655 0.010 -0.095 0.582 -0.042 0.582 
89.0301 6.1 -0.553 0.292 1.284 0.023 0.301 0.343 0.113 0.343 
337.0546 1.2 -0.075 0.777 -0.555 0.027 -0.020 0.933 0.064 0.933 
585.1792 14.8 0.079 0.831 -0.707 0.042 -0.526 0.657 0.270 0.657 
403.0833 1.1 -0.201 0.509 -0.700 0.013 -0.181 0.276 0.021 0.276 
239.0775 1.2 -0.128 0.497 -0.366 0.050 0.035 0.772 -0.020 0.772 
200.0976 6.0 0.221 0.253 -0.269 0.041 0.173 0.344 -0.023 0.344 
173.0088 18.2 -0.011 0.977 -0.937 0.034 0.134 0.550 0.033 0.550 
89.01719 6.1 -0.541 0.343 1.738 0.014 0.184 0.659 0.022 0.659 
192.0232 18.2 0.133 0.745 -0.899 0.043 0.333 0.182 -0.003 0.182 
213.0226 16.9 1.324 0.023 -1.379 0.479 -0.674 0.550 3.047 0.550 
313.0631 13.6 0.266 0.042 -0.201 0.102 0.105 0.764 -0.002 0.764 
313.0545 14.0 0.354 0.043 -0.221 0.207 -0.016 0.968 0.368 0.968 
226.9785 10.9 0.348 0.341 0.054 0.860 -0.207 0.383 -0.842 0.383 
248.9607 10.9 0.365 0.295 0.143 0.623 -0.215 0.390 -0.787 0.390 
227.982 10.9 0.332 0.365 0.088 0.782 -0.219 0.367 -0.866 0.367 
384.9348 10.9 0.594 0.230 0.174 0.668 -0.434 0.100 -1.352 0.100 
113.9883 10.9 0.275 0.331 0.057 0.813 -0.184 0.427 -0.887 0.427 
357.1333 11.0 0.782 0.201 0.153 0.773 -0.339 0.156 -1.140 0.156 
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356.1304 10.9 0.365 0.381 0.001 0.997 -0.310 0.203 -1.080 0.203 
135.045 15.0 0.380 0.587 -0.107 0.836 -0.183 0.871 -7.019 0.871 
112.9853 10.9 0.277 0.304 0.037 0.869 -0.194 0.429 -0.868 0.429 
228.9825 11.0 0.461 0.306 0.122 0.753 -0.216 0.398 -0.876 0.398 
249.9635 10.9 0.353 0.331 0.175 0.551 -0.204 0.405 -0.820 0.405 
154.9734 11.0 0.555 0.226 0.240 0.547 -0.239 0.331 -0.807 0.331 
520.91 10.9 0.734 0.172 0.170 0.674 -0.628 0.036 -1.887 0.036 
152.9778 11.0 0.440 0.271 0.260 0.444 -0.120 0.641 -0.723 0.641 
229.0538 17.2 -1.268 0.481 0.114 0.927 -0.045 0.933 13.217 0.933 
245.0494 15.9 -1.740 0.343 -0.724 0.576 1.037 0.302 9.128 0.302 
112.6942 11.0 0.666 0.133 0.222 0.516 -0.151 0.592 -0.758 0.592 
231.0499 17.1 -1.237 0.590 4.967 0.224 0.000 - 10.855 - 
113.2774 11.0 0.618 0.193 0.416 0.244 -0.160 0.533 -0.913 0.533 
230.0575 17.3 -1.637 0.424 0.065 0.959 -1.585 0.202 17.613 0.202 
227.811 11.1 1.228 0.161 0.758 0.285 -0.216 0.396 -0.948 0.396 
508.2266 17.9 0.959 0.345 2.299 0.089 0.651 0.600 5.938 0.600 
189.0025 15.5 0.383 0.335 -1.258 0.194 -0.028 0.909 -1.365 0.909 
187.0073 15.5 0.330 0.280 -0.864 0.217 -0.053 0.806 -1.296 0.806 
188.01 15.5 0.345 0.365 -1.164 0.180 0.086 0.770 -1.392 0.770 
245.0487 16.7 -0.764 0.212 -0.970 0.351 -0.103 0.842 1.111 0.842 
187.0975 14.7 -0.139 0.641 0.029 0.863 0.080 0.791 -0.642 0.791 
375.2027 14.5 0.953 0.387 -1.623 0.273 0.038 0.926 -0.992 0.926 
171.0059 7.8 0.183 0.353 0.114 0.639 0.295 0.222 -0.670 0.222 
192.0231 14.7 0.229 0.703 1.011 0.132 0.134 0.611 -0.871 0.611 
397.1843 14.6 -2.089 0.331 -2.681 0.332 0.107 0.747 -0.551 0.747 
191.0197 14.9 -0.340 0.518 0.298 0.548 0.101 0.639 -0.782 0.639 
196.0589 1.3 -0.036 0.825 -0.134 0.541 -0.271 0.269 -0.739 0.269 
188.101 14.6 0.007 0.985 0.255 0.310 0.070 0.821 -0.662 0.821 
195.0516 9.9 -0.091 0.861 1.208 0.159 0.256 0.369 1.904 0.369 
545.0154 0.8 0.383 0.092 -0.203 0.302 -0.013 0.890 -0.224 0.890 
295.1228 1.2 -0.080 0.815 0.098 0.779 -0.347 0.318 -0.779 0.318 
294.1195 1.2 -0.137 0.669 0.117 0.729 -0.363 0.267 -0.796 0.267 
383.1223 2.5 -0.198 0.683 0.130 0.771 0.004 0.989 -0.800 0.989 
463.012 0.9 0.301 0.188 -0.223 0.221 0.086 0.430 -0.212 0.430 
356.1711 14.5 -0.798 0.422 -0.312 0.693 0.128 0.628 -0.269 0.628 
180.0664 2.4 -0.066 0.757 0.028 0.867 0.091 0.561 -0.448 0.561 
137.0242 14.6 0.160 0.880 0.908 0.305 0.701 0.209 -0.423 0.209 
328.107 1.6 -0.715 0.114 -0.621 0.055 -0.387 0.173 -0.659 0.173 
223.0821 1.3 0.252 0.280 0.149 0.542 0.062 0.583 -0.431 0.583 
116.0713 1.4 0.119 0.550 0.134 0.520 -0.009 0.954 -0.370 0.954 
330.0336 14.0 0.213 0.397 -0.454 0.069 -0.906 0.353 -3.454 0.353 
361.1404 2.5 -0.098 0.871 0.599 0.335 -0.162 0.731 -1.094 0.731 
227.1016 0.9 0.075 0.733 -0.011 0.954 0.074 0.737 -0.575 0.737 
419.166 14.6 0.000 - 0.000 - 0.152 0.611 -0.293 0.611 
283.1641 2.0 -0.244 0.525 0.397 0.282 -0.286 0.310 -0.400 0.310 
145.0979 0.9 0.119 0.583 -0.166 0.356 0.056 0.794 -0.579 0.794 
165.0747 4.1 -0.035 0.953 0.929 0.189 0.007 0.971 -0.373 0.971 
230.0468 1.7 -0.201 0.415 -0.039 0.864 0.020 0.843 -0.245 0.843 
478.2032 11.0 0.168 0.363 0.047 0.784 0.088 0.730 -0.090 0.730 
164.0716 4.0 0.606 0.112 0.400 0.393 0.049 0.738 -0.340 0.738 
627.0183 0.9 0.361 0.112 -0.230 0.207 0.062 0.435 -0.213 0.435 
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209.0809 14.6 -0.181 0.711 0.125 0.714 0.170 0.521 -0.158 0.521 
217.1078 13.8 -0.477 0.385 -0.158 0.306 0.113 0.701 -0.521 0.701 
154.0123 4.1 0.058 0.922 0.081 0.882 0.340 0.360 -0.789 0.360 
218.1114 13.7 -0.233 0.639 0.072 0.748 0.093 0.770 -0.530 0.770 
212.002 14.6 0.128 0.765 -0.106 0.840 0.120 0.596 -0.636 0.596 
130.0871 2.0 0.065 0.792 0.004 0.986 -0.206 0.309 -0.364 0.309 
373.1868 16.9 -5.228 0.331 0.371 0.855 -0.038 0.916 -0.513 0.916 
276.0546 2.5 0.120 0.677 -0.147 0.485 0.118 0.476 -0.371 0.476 
148.0436 1.7 -0.165 0.476 -0.155 0.351 -0.029 0.838 -0.351 0.838 
151.0257 2.8 2.139 0.329 1.634 0.318 1.193 0.372 -3.471 0.372 
335.0495 5.5 -0.151 0.681 0.138 0.757 0.754 0.093 -0.576 0.093 
145.0386 15.9 -0.095 0.831 -0.415 0.405 0.178 0.520 -0.427 0.520 
296.1352 1.4 -0.225 0.272 -0.119 0.423 -0.165 0.364 -0.303 0.364 
131.0905 2.0 0.029 0.950 0.212 0.573 -0.340 0.343 -0.464 0.343 
243.0624 2.6 -0.109 0.778 0.178 0.578 0.413 0.102 0.493 0.102 
447.035 0.8 0.220 0.269 -0.220 0.318 0.186 0.060 -0.171 0.060 
280.1403 1.4 0.282 0.408 0.696 0.052 -0.241 0.362 -0.547 0.362 
297.1383 1.4 -0.337 0.130 -0.059 0.719 -0.212 0.292 -0.326 0.292 
149.0091 12.1 1.100 0.438 2.153 0.313 2.124 0.181 -1.406 0.181 
530.2386 13.9 -2.166 0.320 -0.144 0.545 -0.161 0.750 1.015 0.750 
170.0432 1.1 -0.047 0.813 -0.247 0.280 -0.180 0.068 -0.276 0.068 
311.1095 1.2 0.017 0.959 0.124 0.724 -0.155 0.443 -0.450 0.443 
172.9911 13.9 0.795 0.244 0.147 0.854 0.393 0.070 -0.522 0.070 
327.1406 1.2 -1.260 0.358 -1.892 0.370 0.151 0.675 -1.155 0.675 
279.8004 12.8 0.406 0.591 0.872 0.281 0.743 0.232 -0.484 0.232 
302.0661 6.5 0.933 0.549 1.181 0.296 0.762 0.333 2.463 0.333 
173.0087 14.9 -0.165 0.653 -0.501 0.234 0.051 0.839 -0.674 0.839 
168.9903 9.3 -0.346 0.394 0.096 0.816 0.179 0.613 -1.199 0.613 
605.1554 13.0 0.181 0.804 1.051 0.181 0.110 0.951 2.024 0.951 
391.0589 13.0 0.560 0.478 0.664 0.414 -0.023 0.918 0.609 0.918 
267.0725 4.4 0.800 0.399 1.102 0.462 1.077 0.306 -4.521 0.306 
150.0124 11.8 -0.395 0.812 2.757 0.187 3.239 0.204 -2.184 0.204 
104.0349 1.2 -0.027 0.939 0.346 0.341 0.074 0.676 -0.400 0.676 
343.995 13.6 -0.092 0.800 -0.119 0.753 1.177 0.391 -1.951 0.391 
317.0451 8.9 0.386 0.303 0.923 0.502 -0.604 0.574 4.367 0.574 
151.0255 3.3 8.517 0.332 8.393 0.333 0.789 0.165 -1.299 0.165 
243.0623 1.7 0.035 0.837 -0.001 0.996 0.276 0.110 -0.230 0.110 
118.0506 1.2 -0.102 0.755 0.018 0.956 0.014 0.907 -0.339 0.907 
173.9942 13.9 1.255 0.182 0.258 0.793 0.535 0.112 -0.738 0.112 
405.0285 12.7 1.228 0.339 0.830 0.373 0.386 0.059 -0.402 0.059 
178.9847 13.3 -0.073 0.920 0.252 0.805 6.700 0.310 5.165 0.310 
367.147 1.2 0.245 0.698 -0.753 0.437 1.592 0.000 0.707 0.000 
346.0926 1.2 -0.236 0.752 -1.514 0.284 1.898 0.000 0.418 0.000 
447.1339 17.7 0.419 0.391 0.239 0.443 -1.139 0.000 -0.314 0.000 
653.3021 18.5 0.638 0.267 0.697 0.060 -0.938 0.005 -0.343 0.005 
649.0095 0.9 0.245 0.199 -0.145 0.486 0.163 0.011 -0.109 0.011 
563.2834 12.2 0.000 - 0.000 - 1.038 0.012 -0.072 0.012 
426.9984 12.8 1.178 0.245 0.368 0.691 1.118 0.013 -0.602 0.013 
201.1245 2.5 0.036 0.904 -0.450 0.198 0.995 0.015 -0.221 0.015 
111.0082 13.9 0.221 0.690 0.747 0.231 0.408 0.016 -0.145 0.016 
519.2073 14.4 -0.233 0.895 0.000 - 1.125 0.018 -0.207 0.018 
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124.0069 1.2 -0.001 0.998 0.094 0.769 0.297 0.018 -0.011 0.018 
238.9932 0.9 0.027 0.912 -0.001 0.997 0.309 0.018 -0.208 0.018 
89.01172 6.1 -0.512 0.221 0.983 0.059 0.517 0.024 -0.275 0.024 
442.972 12.8 1.059 0.334 0.322 0.574 0.526 0.028 -0.257 0.028 
348.1932 12.9 0.306 0.721 -1.504 0.094 0.747 0.029 -0.091 0.029 
197.0318 5.5 -0.783 0.291 0.070 0.796 0.854 0.030 0.345 0.030 
126.0028 1.2 0.101 0.706 0.346 0.320 0.308 0.030 -0.040 0.030 
375.1723 10.9 -0.458 0.471 0.871 0.245 -0.548 0.031 0.090 0.031 
388.03 0.9 0.245 0.162 -0.183 0.308 0.161 0.032 -0.119 0.032 
157.0364 1.3 -0.171 0.557 0.876 0.236 0.545 0.032 -0.160 0.032 
226.9962 4.9 -0.387 0.756 2.514 0.259 1.204 0.033 0.725 0.033 
156.9904 0.9 0.033 0.903 0.170 0.544 0.350 0.034 -0.212 0.034 
451.2199 12.7 2.525 0.331 2.781 0.333 -0.615 0.036 0.116 0.036 
726.3473 13.5 0.000 - 4.264 0.333 0.764 0.042 -0.055 0.042 
567.007 0.9 0.202 0.272 -0.138 0.499 0.158 0.043 -0.130 0.043 
152.0431 14.4 -0.463 0.259 0.556 0.524 0.521 0.045 0.238 0.045 
171.9862 7.3 0.623 0.150 0.625 0.329 0.204 0.045 -0.157 0.045 
88.01147 7.5 0.138 0.784 1.285 0.142 0.343 0.048 -0.106 0.048 
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226.9785 10.9 0.348 0.341 0.054 0.860 -0.207 0.383 -0.842 <0.001 
248.9607 10.9 0.365 0.295 0.143 0.623 -0.215 0.390 -0.787 <0.001 
227.982 10.9 0.332 0.365 0.088 0.782 -0.219 0.367 -0.866 <0.001 
384.9348 10.9 0.594 0.230 0.174 0.668 -0.434 0.100 -1.352 <0.001 
113.9883 10.9 0.275 0.331 0.057 0.813 -0.184 0.427 -0.887 <0.001 
357.1333 11.0 0.782 0.201 0.153 0.773 -0.339 0.156 -1.140 <0.001 
356.1304 10.9 0.365 0.381 0.001 0.997 -0.310 0.203 -1.080 <0.001 
135.045 15.0 0.380 0.587 -0.107 0.836 -0.183 0.871 -7.019 <0.001 
112.9853 10.9 0.277 0.304 0.037 0.869 -0.194 0.429 -0.868 <0.001 
228.9825 11.0 0.461 0.306 0.122 0.753 -0.216 0.398 -0.876 <0.001 
249.9635 10.9 0.353 0.331 0.175 0.551 -0.204 0.405 -0.820 <0.001 
154.9734 11.0 0.555 0.226 0.240 0.547 -0.239 0.331 -0.807 <0.001 
520.91 10.9 0.734 0.172 0.170 0.674 -0.628 0.036 -1.887 0.001 
152.9778 11.0 0.440 0.271 0.260 0.444 -0.120 0.641 -0.723 0.001 
229.0538 17.2 -1.268 0.481 0.114 0.927 -0.045 0.933 13.217 0.001 
245.0494 15.9 -1.740 0.343 -0.724 0.576 1.037 0.302 9.128 0.001 
112.6942 11.0 0.666 0.133 0.222 0.516 -0.151 0.592 -0.758 0.001 
231.0499 17.1 -1.237 0.590 4.967 0.224 0.000 - 10.855 0.001 
113.2774 11.0 0.618 0.193 0.416 0.244 -0.160 0.533 -0.913 0.001 
230.0575 17.3 -1.637 0.424 0.065 0.959 -1.585 0.202 17.613 0.001 
227.811 11.1 1.228 0.161 0.758 0.285 -0.216 0.396 -0.948 0.001 
505.208 18.2 -0.104 0.885 2.589 0.000 -5.010 0.337 14.896 0.001 
508.2269 18.1 0.878 0.367 3.218 0.009 0.665 0.595 5.969 0.001 
508.2266 17.9 0.959 0.345 2.299 0.089 0.651 0.600 5.938 0.001 
507.2234 18.2 0.852 0.389 3.103 0.007 1.096 0.621 8.712 0.001 
213.0226 16.9 1.324 0.023 -1.379 0.479 -0.674 0.550 3.047 0.001 
189.0025 15.5 0.383 0.335 -1.258 0.194 -0.028 0.909 -1.365 0.001 
187.0073 15.5 0.330 0.280 -0.864 0.217 -0.053 0.806 -1.296 0.001 
188.01 15.5 0.345 0.365 -1.164 0.180 0.086 0.770 -1.392 0.001 
245.0487 16.7 -0.764 0.212 -0.970 0.351 -0.103 0.842 1.111 0.001 
187.0975 14.7 -0.139 0.641 0.029 0.863 0.080 0.791 -0.642 0.001 
509.2314 18.1 0.893 0.350 3.136 0.013 0.000 - 5.001 0.001 
375.2027 14.5 0.953 0.387 -1.623 0.273 0.038 0.926 -0.992 0.001 
171.0059 7.8 0.183 0.353 0.114 0.639 0.295 0.222 -0.670 0.001 
192.0231 14.7 0.229 0.703 1.011 0.132 0.134 0.611 -0.871 0.001 
397.1843 14.6 -2.089 0.331 -2.681 0.332 0.107 0.747 -0.551 0.001 
191.0197 14.9 -0.340 0.518 0.298 0.548 0.101 0.639 -0.782 0.001 
196.0589 1.3 -0.036 0.825 -0.134 0.541 -0.271 0.269 -0.739 0.001 
188.101 14.6 0.007 0.985 0.255 0.310 0.070 0.821 -0.662 0.001 
195.0516 9.9 -0.091 0.861 1.208 0.159 0.256 0.369 1.904 0.001 
310.1509 1.9 -0.349 0.560 -1.113 0.039 -0.417 0.193 -0.582 0.001 
545.0154 0.8 0.383 0.092 -0.203 0.302 -0.013 0.890 -0.224 0.001 
295.1228 1.2 -0.080 0.815 0.098 0.779 -0.347 0.318 -0.779 0.001 
294.1195 1.2 -0.137 0.669 0.117 0.729 -0.363 0.267 -0.796 0.001 
383.1223 2.5 -0.198 0.683 0.130 0.771 0.004 0.989 -0.800 0.002 
463.012 0.9 0.301 0.188 -0.223 0.221 0.086 0.430 -0.212 0.002 
356.1711 14.5 -0.798 0.422 -0.312 0.693 0.128 0.628 -0.269 0.002 
180.0664 2.4 -0.066 0.757 0.028 0.867 0.091 0.561 -0.448 0.003 
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137.0242 14.6 0.160 0.880 0.908 0.305 0.701 0.209 -0.423 0.003 
328.107 1.6 -0.715 0.114 -0.621 0.055 -0.387 0.173 -0.659 0.003 
223.0821 1.3 0.252 0.280 0.149 0.542 0.062 0.583 -0.431 0.003 
116.0713 1.4 0.119 0.550 0.134 0.520 -0.009 0.954 -0.370 0.003 
330.0336 14.0 0.213 0.397 -0.454 0.069 -0.906 0.353 -3.454 0.004 
361.1404 2.5 -0.098 0.871 0.599 0.335 -0.162 0.731 -1.094 0.004 
227.1016 0.9 0.075 0.733 -0.011 0.954 0.074 0.737 -0.575 0.005 
419.166 14.6 0.000 - 0.000 - 0.152 0.611 -0.293 0.005 
283.1641 2.0 -0.244 0.525 0.397 0.282 -0.286 0.310 -0.400 0.006 
145.0979 0.9 0.119 0.583 -0.166 0.356 0.056 0.794 -0.579 0.006 
165.0747 4.1 -0.035 0.953 0.929 0.189 0.007 0.971 -0.373 0.007 
230.0468 1.7 -0.201 0.415 -0.039 0.864 0.020 0.843 -0.245 0.007 
330.0336 13.8 0.294 0.185 -0.429 0.049 -0.621 0.488 -2.566 0.007 
478.2032 11.0 0.168 0.363 0.047 0.784 0.088 0.730 -0.090 0.007 
164.0716 4.0 0.606 0.112 0.400 0.393 0.049 0.738 -0.340 0.008 
627.0183 0.9 0.361 0.112 -0.230 0.207 0.062 0.435 -0.213 0.009 
209.0809 14.6 -0.181 0.711 0.125 0.714 0.170 0.521 -0.158 0.009 
217.1078 13.8 -0.477 0.385 -0.158 0.306 0.113 0.701 -0.521 0.010 
154.0123 4.1 0.058 0.922 0.081 0.882 0.340 0.360 -0.789 0.010 
218.1114 13.7 -0.233 0.639 0.072 0.748 0.093 0.770 -0.530 0.010 
212.002 14.6 0.128 0.765 -0.106 0.840 0.120 0.596 -0.636 0.010 
130.0871 2.0 0.065 0.792 0.004 0.986 -0.206 0.309 -0.364 0.013 
373.1868 16.9 -5.228 0.331 0.371 0.855 -0.038 0.916 -0.513 0.013 
276.0546 2.5 0.120 0.677 -0.147 0.485 0.118 0.476 -0.371 0.015 
148.0436 1.7 -0.165 0.476 -0.155 0.351 -0.029 0.838 -0.351 0.015 
151.0257 2.8 2.139 0.329 1.634 0.318 1.193 0.372 -3.471 0.017 
335.0495 5.5 -0.151 0.681 0.138 0.757 0.754 0.093 -0.576 0.017 
145.0386 15.9 -0.095 0.831 -0.415 0.405 0.178 0.520 -0.427 0.017 
296.1352 1.4 -0.225 0.272 -0.119 0.423 -0.165 0.364 -0.303 0.018 
131.0905 2.0 0.029 0.950 0.212 0.573 -0.340 0.343 -0.464 0.018 
243.0624 2.6 -0.109 0.778 0.178 0.578 0.413 0.102 0.493 0.020 
447.035 0.8 0.220 0.269 -0.220 0.318 0.186 0.060 -0.171 0.022 
280.1403 1.4 0.282 0.408 0.696 0.052 -0.241 0.362 -0.547 0.022 
297.1383 1.4 -0.337 0.130 -0.059 0.719 -0.212 0.292 -0.326 0.023 
149.0091 12.1 1.100 0.438 2.153 0.313 2.124 0.181 -1.406 0.024 
530.2386 13.9 -2.166 0.320 -0.144 0.545 -0.161 0.750 1.015 0.025 
170.0432 1.1 -0.047 0.813 -0.247 0.280 -0.180 0.068 -0.276 0.027 
311.1095 1.2 0.017 0.959 0.124 0.724 -0.155 0.443 -0.450 0.028 
172.9911 13.9 0.795 0.244 0.147 0.854 0.393 0.070 -0.522 0.028 
327.1406 1.2 -1.260 0.358 -1.892 0.370 0.151 0.675 -1.155 0.028 
200.0543 1.2 -0.029 0.883 -0.422 0.018 -0.121 0.302 -0.369 0.030 
279.8004 12.8 0.406 0.591 0.872 0.281 0.743 0.232 -0.484 0.033 
302.0661 6.5 0.933 0.549 1.181 0.296 0.762 0.333 2.463 0.034 
173.0087 14.9 -0.165 0.653 -0.501 0.234 0.051 0.839 -0.674 0.034 
168.9903 9.3 -0.346 0.394 0.096 0.816 0.179 0.613 -1.199 0.037 
605.1554 13.0 0.181 0.804 1.051 0.181 0.110 0.951 2.024 0.037 
391.0589 13.0 0.560 0.478 0.664 0.414 -0.023 0.918 0.609 0.038 
267.0725 4.4 0.800 0.399 1.102 0.462 1.077 0.306 -4.521 0.038 
150.0124 11.8 -0.395 0.812 2.757 0.187 3.239 0.204 -2.184 0.039 
104.0349 1.2 -0.027 0.939 0.346 0.341 0.074 0.676 -0.400 0.040 
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343.995 13.6 -0.092 0.800 -0.119 0.753 1.177 0.391 -1.951 0.040 
317.0451 8.9 0.386 0.303 0.923 0.502 -0.604 0.574 4.367 0.041 
151.0255 3.3 8.517 0.332 8.393 0.333 0.789 0.165 -1.299 0.041 
243.0623 1.7 0.035 0.837 -0.001 0.996 0.276 0.110 -0.230 0.042 
118.0506 1.2 -0.102 0.755 0.018 0.956 0.014 0.907 -0.339 0.042 
173.9942 13.9 1.255 0.182 0.258 0.793 0.535 0.112 -0.738 0.045 
405.0285 12.7 1.228 0.339 0.830 0.373 0.386 0.059 -0.402 0.046 
178.9847 13.3 -0.073 0.920 0.252 0.805 6.700 0.310 5.165 0.048 
159.1678 12.8 1.524 0.381 -3.204 0.369 0.185 0.199 -0.213 0.049 
506.2108 18.2 -0.451 0.664 2.764 0.000 -5.027 0.337 -4.737 0.337 
261.0588 1.2 -0.251 0.312 -0.583 0.007 -0.195 0.356 -0.093 0.520 
523.2189 17.3 -0.333 0.687 3.920 0.009 -0.964 0.567 -1.435 0.434 
321.0806 1.1 -0.172 0.569 -0.655 0.010 -0.095 0.582 -0.042 0.681 
403.0833 1.1 -0.201 0.509 -0.700 0.013 -0.181 0.276 0.021 0.877 
206.01 1.2 -0.026 0.894 -0.464 0.013 0.068 0.541 0.107 0.430 
89.01719 6.1 -0.541 0.343 1.738 0.014 0.184 0.659 0.022 0.949 
258.1573 5.6 -0.264 0.521 -0.897 0.017 0.016 0.836 0.368 0.228 
253.6102 18.4 1.227 0.260 3.722 0.020 0.000 - 0.000 - 
227.0648 1.2 0.033 0.819 -0.358 0.023 -0.151 0.140 0.092 0.389 
89.0301 6.1 -0.553 0.292 1.284 0.023 0.301 0.343 0.113 0.738 
329.03 14.0 0.250 0.158 -0.432 0.026 0.194 0.482 0.174 0.241 
337.0546 1.2 -0.075 0.777 -0.555 0.027 -0.020 0.933 0.064 0.746 
309.068 1.1 0.105 0.607 -0.471 0.030 -0.148 0.282 0.186 0.095 
173.0088 18.2 -0.011 0.977 -0.937 0.034 0.134 0.550 0.033 0.885 
583.1746 15.2 0.039 0.930 -0.884 0.034 -0.344 0.801 -1.297 0.426 
89.03577 6.1 -0.387 0.354 1.303 0.036 0.575 0.023 -0.217 0.484 
124.991 5.6 -0.097 0.759 -0.823 0.037 0.280 0.368 0.478 0.133 
281.0991 1.2 -0.082 0.866 -1.194 0.037 1.691 0.000 0.569 0.212 
187.0011 6.4 0.133 0.690 1.221 0.039 0.514 0.050 0.288 0.419 
292.084 16.7 0.105 0.770 -0.747 0.040 0.185 0.526 0.117 0.109 
200.0976 6.0 0.221 0.253 -0.269 0.041 0.173 0.344 -0.023 0.883 
585.1792 14.8 0.079 0.831 -0.707 0.042 -0.526 0.657 0.270 0.831 
192.0232 18.2 0.133 0.745 -0.899 0.043 0.333 0.182 -0.003 0.979 
351.0114 14.1 0.240 0.291 -0.481 0.043 0.101 0.698 0.145 0.482 
345.0043 10.3 -0.100 0.920 -3.046 0.047 0.480 0.269 0.453 0.376 
152.9957 6.2 0.493 0.562 1.585 0.047 -0.308 0.820 -0.885 0.505 
90.02714 6.0 -0.498 0.222 0.911 0.050 0.307 0.143 -0.114 0.666 
239.0775 1.2 -0.128 0.497 -0.366 0.050 0.035 0.772 -0.020 0.877 
111.0084 18.2 0.091 0.832 -0.904 0.053 0.450 0.050 -0.157 0.365 
215.0672 7.4 -0.867 0.507 -2.218 0.053 -0.813 0.393 -0.122 0.875 
154.9961 7.5 0.232 0.697 1.261 0.056 0.014 0.898 -0.088 0.535 
188.66 16.4 0.148 0.642 -0.707 0.056 -0.299 0.289 -0.175 0.475 
173.9863 11.1 -0.991 0.275 -1.870 0.057 1.583 0.336 0.285 0.779 
622.1246 14.6 0.181 0.592 -0.632 0.057 1.118 0.605 0.000 - 
89.01172 6.1 -0.512 0.221 0.983 0.059 0.517 0.024 -0.275 0.387 
345.0037 9.6 -0.243 0.852 -3.033 0.060 0.461 0.281 0.328 0.517 
191.0197 18.1 0.100 0.791 -0.798 0.060 0.246 0.246 -0.110 0.421 
653.3021 18.5 0.638 0.267 0.697 0.060 -0.938 0.005 -0.343 0.349 
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